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Chapter 1 
 
Rigid Luminescent bis-Zinc(II)-bis-Cyclen Complexes for 
the Detection of Phosphate Anions and Non-covalent 
Protein Labeling in Aqueous Solution 
 
 
 
 
 
 
 
“Beyond molecular chemistry based on the covalent bond, there lies the field of 
Supramolecular Chemistry, whose goal is to gain control over the intermolecular 
interactions” 
-Jean Marie Lehn 
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1.1 General Introduction 
1.1.1 Selective labeling of proteins: Background 
Protein labeling with chemically modified small molecular probe is an important tool for 
sensing and visualizing protein dynamics, localization, functions and protein-protein interaction in 
vivo. It is an invaluable technique to understand protein functions and networks in living cells. 
Genetically encoded fluorescent protein (FPs and GFPs) is the most popular technique for protein 
labeling[1] in protein research and this has allowed a wide range of studies in living cells with high 
labeling specificity.[2] 
 
 
Figure 1: The principle of GFP labeling. (a) The structure of GFP. (b) Schematic representation of a 
recombinant gene containing cDNA of a target molecule fused to that of GFP. The expression of the 
recombinant gene in cells allows the observation of the recombinant protein with excitation and emission 
wavelengths of GFP at 488 and 510 nm, respectively [Reprinted with permission from the quoted reference] [3] 
 
However this technique has some potential disadvantages. First is, these fluorescent proteins 
are large enough to interfere with the localization, structure or activity of the proteins to which they 
are fused and second, these fluorescent proteins are poor probes for environmental cues like pH, 
hydrophobicity and ion concentrations.[4] All these led to the current efforts to develop alternate 
technique of proteins by chemically modified small luminescent markers or affinity tags. Based on 
binding mechanisms, most chemical labeling techniques can be classified into two major categories; 
enzymatic labeling and affinity labeling. Enzymatic labeling involves covalent labeling while affinity 
labeling deals with non-covalent methods to label proteins. There are several reports of enzymatic 
labeling on protein research and some remarkable examples include: covalent modification of fusion 
proteins on cell surface like acyl carrier protein (ACP) by phosphopantetheine transferase (PPTase),[5] 
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site specific introduction of genetically encoded aldehyde tag into formylglycine generating 
enzyme,[6] sequential labeling of fusion proteins of O6-alkylguanine-DNA alkyltransferase (AGT) 
with different fluorophores in mammalian cells,[7] selective labeling of farnesylation motif proteins by 
using protein farnesyltransferase (PFTase).[8] Although the permanence of covalent labeling allows 
unambiguous analyses of the protein after labeling,[9] this method is irreversible and also often the 
covalent modifications of proteins involves tedious synthesis. Non-covalent labeling of protein is free 
from the limitations of covalent labeling and reversibility of this method can be considered as the 
primary advantage. The non-covalent methods include several high affinity snap tags, antibodies and 
metal chelation methods.[10]  
 
 
 
Figure 2: Chemical labeling of proteins of interest (POI) with small fluorescent molecules based on metal-
chelation (a) tetracysteine/biarsenical system (b) oligo-aspartate/zinc-complex system [adapted from the quoted 
reference][1] 
 
1.1.2 Recognition of biologically relevant phosphates in aqueous solution: Snippets 
Phosphates are ubiquitously present in nature and they are an integral part of recognition 
events involving proteins, nucleic acids, cofactors, and antibodies. Phosphates are vividly present in 
RNA and DNA, in phosphorylated saccharides and phosphorylated proteins.[11] Protein 
phosphorylation plays a significant role in a wide range of cellular processes. The nucleotide, 
adenosine triphosphate (ATP), is the universal energy currency for metabolism and involved in 
1. Rigid Luminescent bis-Zinc(II)-bis-Cyclen Complexes for the Detection of Phosphate Anions and non-
covalent Protein Labeling in Aqueous Solution    
 
 
  4 
intracellular energy transport for various metabolic processes including biosynthetic reactions, 
mobility, and cell division. The hydrolysis of ATP in cells produces pyrophosphate (PPi) along with 
AMP and it plays an important role in intracellular signaling.[12] Hence development of artificial 
phosphate anion receptors is of immense importance to understand numerous biological processes. 
 
Figure 3: Schematic representation of reversible protein phosphorylation by kinase [adapted from the quoted 
reference][13]  
 
Transition metal complexes with vacant coordination sites are well suited to serve as 
phosphate ion binding sites.[14] Some metal complexes were reported to show selective binding to 
biologically relevant phosphates and were used as binding receptor moieties in phosphate recognition: 
Zinc(II)-dipicolylamine (Dpa) complexes as demonstrated by Hamachi,[15] Hong[16] and Smith[17] and 
macrocyclic 1,4,7,10- tetraazacyclododecane (cyclen) transition metal complexes reported  by 
Kikuchi[18] and Kimura.[19] 
 
 
Figure 4: Some of the metal complexes widely used as binding receptors in phosphate recognition [15, 19] 
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1.2 Outline of the chapter1 
In this chapter the synthesis of a series of water soluble bis- and tetrakis-Zn(II)-cyclen 
complexes with rigid structures is reported, which were designed to enhance the carboxylate and 
phosphate ion binding response in contrast to analogues with less confined molecular structure.  Boc-
protected 6-chloro-1, 3, 5-triazine-bis cyclen was coupled to different aryl and alkyl moieties in 
moderate to high yields and subsequently converted into the corresponding bis- or tetrakis-Zn(II)-
cyclen complexes. The bis-Zn(II)-cyclen moiety is known for its affinity to anions. Depending on the 
arene substituent some of the synthesized synthetic receptors are luminescent. They were studied by 
absorption and emission spectroscopy for their response to the presence of phosphate anions of 
biological relevance in buffered aqueous solution at neutral pH and for their affinity to the genetically 
encodable oligo-aspartate and glutamate sequences (D4- and E4-tag) recently introduced by Hamachi 
et al. The rigid structures of the compounds enhance the electronic coupling between the metal 
complex binding site and the reporter dye. This leads to an increased anion binding response in 
homogeneous aqueous solution. 
1.3 Results and Discussions2 
1.3.1 Synthesis of Zn(II)-cyclen complexes  
The rigid bis-Zn(II)-cyclen based receptors are synthesized mainly by using Suzuki-Miyaura 
cross coupling reactions as shown in Scheme 1.  
Threefold Boc-protected bis-cyclen and compound 1 were synthesized following an earlier 
reported procedure.[20] The protection of the cyclen azamacrocycle reduces polarity and prevents 
multi-N-substitution. Trichlorotriazine reacts with two equivalents of threefold Boc-protected cyclen 
yielding 1 in a clean twofold nucleophilic aromatic substitution. The remaining chloro substituent of 
the triazine bis-cyclen 1 was then used for coupling with different boronic acids 2 via palladium 
catalyzed Suzuki-Miyaura reaction. The synthesized ligands 3 are listed in the Table 1 with their 
isolated yields. The obtained Boc-protected cyclen ligands 3 were deprotected with trifluoroacetic 
acid to give the corresponding ammonium salts in quantitative yields. Finally, complexation of the 
azamacrocyclic amines with ZnCl2 gave the Zn(II)-cyclen complexes 4. 
                                                            
1 M. Bhuyan, E. Katayev, S. Stadlbauer, H. Nonaka, A. Ojida, I. Hamachi, B. König Eur. J. Org. Chem. 2011, 
2011, 2807. 
2 All compounds were synthesized at University of Regensburg by Mouchumi Bhuyan. The peptide tags used 
were provided by the group of Itaru Hamachi, Kyoto University, Japan. All the investigations were carried out 
at University of Regensburg. 
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Complex 4c was characterized with the help of single crystal diffraction analysis. In order to 
obtain suitable crystals a small access of zinc(II) chloride present in the aqueous solution was used for 
crystallization. This conditions led to the formation of complex [(4c-2Cl-) 2+][ZnCl42-] (Figure 1). The 
cyclen moieties coordinate to zinc cations with typical Zn-N distances of 2.1Ǻ to the three aliphatic 
nitrogen atoms and one longer Zn-N distance of 2.6Ǻ to the triazine nitrogen. The anthracene ring is 
twisted from the triazine plane by a torsion angle of 68°. 
 
 
Scheme 1: The synthesis of triazine bis-Zn (II)-cyclen complexes 4a – h 
 
Figure 5: ORTEP rendered view of the molecular structure of complex 4c. Hydrogen atoms, methanol and the 
ZnCl42- anion are omitted for clarity. Ellipsoids are shown in 50% probability level. 
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Table 1: Structures and isolated yields of the synthesized bis- and tetrakis Boc-protected cyclen ligands 3a-h 
obtained by Suzuki-Miyaura cross coupling strategy 
Entry Boronic acids 2 Protected Ligands 3 Isolated Yield [%] 
 
1 
 
3a 
50 
2 
 
 
3b 
31 
3 
 
 
3c 
50 
4 
 
 
3d 
30 
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In the attempts to include rigidity in bis-Zn(II)-cyclen complexes, apart from Suzuki-Miyaura 
cross coupling strategy, Sonogashira cross coupling has also been tried (Scheme 2), but this strategy 
has not been further developed due to the unsatisfactory chemical yields. 
 
5 
 
 
3e 
54 
6 
 
3f 
52 
7 
 
3g 
78 
8 
 
3h 
47 
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Scheme 2: The synthesis of modified triazine bis-cyclen ligand 5, for potential metal complexation using 
Sonogashira cross coupling strategy 
1.3.2  UV-visible and luminescent properties of Zn(II)-cyclen complexes 
Some of the synthesised complexes 4 bear fluorophores and their UV-visible and luminescent 
properties were investigated. The data are summarized in Table 2. 
 
  Absorption[a] Emission[b]
Complexes λmax log ε λexcitation [nm] λmax [nm] Φrel (%)[c] 
4a 224 4.44 230 457 0.02 
4b 285 4.53 290 385 0.2 
4c 365 3.90 364 455 2.0 
4d 370 3.36 372 456 20 
4e 350 4.16 354 453 5.9 
4g 220 4.10 220 424 0.02 
[a] Measured in HEPES buffer at a concentration of c = 10-4 mol/L. [b] Measured in HEPES buffer at a concentration of c = 
10-5 mol/L. [c] Relative quantum yields were determined using quinine sulphate (ΦQuinine sulphate  = 58%).[21] 
Table 2: Absorption and emission data of the synthesized complexes 4a-e and 4g [All compounds have similar 
emission maxima in HEPES buffer] The emission quantum yields of the synthesised complexes were measured 
in methanol as solvent with quinine sulphate as reference to explore variations of the photo physical properties.  
 Highest quantum yields are observed for compounds 4b-4e. These compounds were studied 
in detail using fluorescence titrations in 25 mM HEPES buffer, pH 7.4 at 25°C and binding affinities 
for carboxylates and phosphates were determined. The concentration of HEPES buffer was chosen to 
cover the range of binding affinities which are characteristic for complexes 4b-4e. We were interested 
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to compare the selectivities of binding and emission responses of rigid bis- and tetra-Zn(II) complexes 
arising from the interaction with different anions. The studies performed by the Hamachi group using 
Zn(II)-Dpa-Tyr and a series of oligo-aspartate peptides (Boc-Dn-NH2, n = 2 – 5) and oligo-glutamate 
peptides (Boc-En-NH2, n = 3, 4) revealed that D4-tag (n= 4) has the highest affinity.[22] Based on the 
reported results, we selected D4- and E4-tag sequences for our investigations. The derived binding 
affinities of the complexes with the carboxylates, pyrophosphate (PPi) and O-phospho-L-serine are 
shown in Table 3. Analysis of fluorescence responses (F/F0) in Table 3 reveals that in most cases the 
coordination of a guest to a zinc complex leads to an increase of emission. This is in good agreement 
with reports on Zn2+-DPA complexes.16d  
 Boc-E4-NH2 Boc-D4-NH2 PPi O-Phospho-
L-serine 
4d  logβ21=13.46(12) 
logβ11=7.21(6) 
logβ21=16.22(8) 
logβ11 > 7 
[b] logβ11<3 
H:G ratio, F/F0[a]          1:1, 6.8         1:1, 4.8         1:2, 5.5      1:1, 1.21  
4b  logβ21=12.24(8) 
logβ11=6.74(3) 
logβ11 > 7 
logβ12=13.38(8) 
[b]  [c] 
H:G ratio, F/F0[a]         1:1, 2.2          1:2, 1.3          1:2, 0.1    
4c  logβ11=3.41(1) logβ11=3.31(1) [b] [c] 
H:G ratio, F/F0[a]          1:1, 1.3           1:1, 1.8         1:1, 3.4    
4e  logβ11 < 3 logβ11 < 3 logβ21=11.05(7)  
logβ22=16.55(12) 
[c] 
H:G ratio, F/F0[a]        1:1,0.9           1:1, 0.9        1:1, 1.2    
[a] Stoichiometry of host (H) : guest (G) ration was determined according to Job's method; F/F0 = changes in fluorescence of 
zinc complex upon addition of one equivalent of a guest. [b]Good fitting of the experimental curve was not possible; each 
stepwise binding constant was of the range of > 106 M-1. [c]Changes in fluorescence response upon titration with guest were 
negligible. 
Table 3: Binding characteristics of complexes 4b–e measured as 0.01–0.05 mm solutions in 25 mm HEPES 
buffer, pH 7.4, 25 °C 
According to our ESI mass spectroscopy investigations, at the concentration required for fluorescence 
measurement some di- and tri-nuclear zinc complexes are formed from the parent tetranuclear zinc 
complexes. They are weakly fluorescent due to quenching by photoinduced electron transfer (PET) 
from the uncomplexed aliphatic nitrogens. The coordination of an anion induces complete Zn2+-cation 
1. Rigid Luminescent bis-Zinc(II)-bis-Cyclen Complexes for the Detection of Phosphate Anions and non-
covalent Protein Labeling in Aqueous Solution    
 
 
  11 
coordination to the nitrogen ligand and thus decreases PET quenching,  [23] which results in a turn-on 
response. The presence of this mechanism was proved by addition of an excess of zinc (II) chloride to 
complexes, in this case slight increase (1.1-1.4 fold) of fluorescence was observed. However, the 
coordination of E4- and D4-tag to complex 4d led to much larger increase of fluorescence - 6.8 and 
4.8, respectively. This data indicate that another turn-on mechanism is also present: The coordination 
of a guest rigidifies the structure leading to a significant emission increase. 
1.3.3 Coordination of tetra-aspartate (Boc-D4-NH2) and tetra-glutamate (Boc-E4-NH2) 
peptides sequences 
Coordination of D4 or E4 peptide sequences to bis-Zn(II) complexes 4c and 4e is rather weak 
and only small changes in fluorescence are observed upon addition of ca. 10 equivalents of a guest. 
The tetra-Zn(II) complexes have much higher binding affinities for both E4- and D4-tags with stepwise 
binding constants of ca. 107 M-1. Such a dramatic increase is explained by the increased coulombic 
interaction in a host-guest complex. The characteristic changes in emission and the binding isotherm 
for tetra-Zn(II) complex 4d are shown in Figure 6. 
        
Figure 6: Changes of fluorescence of tetra-Zn(II) complex 4d upon addition of the E4-tag. Experimental points 
on the binding isotherm are shown as rhombuses. The titrations were carried out in 25 mM HEPES buffer, pH 
7.4, at 25°C, excitation wavelength λex=320 nm. 
 Binding isotherms were fitted to a model of stepwise 2:1, 1:1 and 1:2 binding. Aggregate 
formation with a 2:1 stoichiometry appears only due to the addition of a mM solution of the guest to 
the µM solution of a host. During first additions the complex is in large excess, thus several molecules 
of the later can coordinate to the tetracarboxylate. The other binding stoichiometries were observed in 
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solution and confirmed by ESI spectrometry. Comparison of the calculated and experimentally found 
isotope distribution of the molecular ions is shown in Figure 7. 
 
(a) (b) (c) 
Figure 7: Comparison of the calculated (lower) and observed (upper) isotope distribution for ions: (a) m/z=923 
[4d-8Cl-+D4-6H]2+ and (b) m/z=1160 [4b-8Cl-+2D4-6H]2+ (c) Proposed geometry of receptor–peptide tag 
aggregate of 4b with two molecules of D4-tag. 
In order to understand the mode of interactions between the oligopeptide and the tetrazinc 
complexes we have conducted DFT (B3LYP, 6-31G*) calculations using Spartan’06 (Wavefunction 
Inc.). According to the calculations the scaffold of the two benzene linked binuclear Zn(II)-cyclen 
complexes (4b) perfectly matches the oligo peptide tags (D4, E4) structure and charge distribution. In 
a sandwich-like aggregate of 4b and the tag protein strong electrostatic interactions are likely, 
resulting in the observed high apparent binding affinity. The electrostatic potential surface is 
displayed as wired mesh of the D4-tag in Figure 7. The red colour indicates a high density of negative 
charges at the carboxylate residues of the tag. The cationic Zn(II)-cyclen favourably interacts with the 
anionic carboxylate residues. The figure shows a sandwich-like 1:2 receptor–peptide tag aggregate 
formation of 4b and the D4-tag. The energy minimized structure of 4d shows that unlike 4b, where 
benzene and triazine moieties are in plane, the plane of anthracene is perpendicular to the plane of the 
triazine. This creates steric hindrance, which may be responsible for the observed 1:1 receptor to 
peptide binding stoichiometry in case of 4d. The predicted twisted conformation of the triazine 
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anthracene moiety of complex 4d is in a good agreement with the crystal structure of bis-Zn(II)-
anthracene complex 4c. 
1.3.4 Coordination of phosphate anions 
Bis-Zn(II)-cyclen complexes show high affinity for phosphate anions in aqueous solution, 
which is of interest for potential applications in biological phosphate recognition. However, the so far 
developed bis-Zn(II)-cyclen based synthetic receptors have flexible spacers between the receptor 
moiety and the signalling unit. Due to this flexibility, the luminescent group cannot respond 
effectively to the binding event by a change in its emission properties. Figure 8 shows one of our 
previously reported complexes with flexible linker between fluorophore and the receptor and its 
negligible change emission properties in presence of analytes in homogeneous solution.[24] 
 
Figure 8: Dinuclear Zn(II)-cyclen dansyl complex with flexible linker between receptor and fluorophore (left); 
emission intensity changes of binuclear Zn(II)-cyclen dansyl complex (80 μM in HEPES buffer, pH 7.4, λex = 
330 nm, 25 °C) upon addition of various nucleotides and phosphates (right). 
 
In the here reported synthesised bis-Zn(II)-cyclen complexes, the rigid molecular structure 
and the direct conjugation of the central triazine unit to the arenes allows the transmission of the anion 
binding event at the cyclen complex to the signalling unit, which response by changes of the emission 
properties (Table 3). The affinities of the complexes for monophosphate anions such as 
phenylphosphate or O-phospho-L-serine are rather small, but excellent for polyphosphates. The most 
efficient response was observed for bis-Zn(II)-anthracene containing complex 4c, whose fluorescence 
is 3.4 fold increased upon addition of one equiv. of pyrophosphate. The sensitivity for pyrophosphate 
is even higher for tetra-Zn(II) complexes: 5.5 and 0.1 fold change in fluorescence for anthracene (4d) 
and benzene (4b) containing complexes, respectively (Table 3). Complexes 4b and 4d have opposite 
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responses: the presence of pyrophosphate quenches the fluorescence of 4b, but strongly increases the 
fluorescence of 4d (Figure 9).  
  
(a) (b) 
Figure 9: Fluorescence response upon addition of sodium pyrophosphate to the solution of (a) complex 4b and 
solution of (b) complex 4d. Titrations were carried out in 25 mM HEPES buffer, pH 7.4, at 25°C. 
Though the affinities of tetra-Zn(II) complexes for pyrophosphate were good it was difficult 
to fit binding isotherms with typical models. Job's plot analysis showed that tetra-Zn(II) complexes 
bind pyrophosphate in a 1:2 stoichiometry. Using this model we were able to obtain a stepwise 
binding constant in the order 107 M-1 (Table 3). The binding isotherm of bis-Zn(II) complex 4c  was 
successfully fitted using a 2:1 and 2:2 stepwise binding model. Additional proof for the formation of 
the complex with a 2:2 stoichiometry were obtained using ESI mass spectrometry, where the complex 
with the composition [(4c-4Cl-+PPi4-+Na+)2]2+ was one of the major peaks (Supporting data, Figure 
19). Thus, coordination of pyrophosphate to 4c induces dimerization of the complex. This observation 
led us to suggest that strong quenching of the fluorescence of complex 4b upon interaction with 
pyrophosphate can arise from a similar dimerization resulting in π-π stacking interactions of planar 
benzene-triazine moieties (Figure 10(c)). This could not be the case for anthracene-containing tetra-
Zn(II) complex, because it does not have a planar structure according to DFT calculations of 4d and 
the X-ray structure of 4c, thus close interaction of the anthracene rings is not sterically favourable. To 
prove the dimerization of 4b we have conducted ESI measurements of both complexes 4b and 4d in 
the presence of excess of pyrophosphate in aqueous solution. Though the major peaks for both 
complexes corresponded to [4b-8Cl-+2PPi4-+2Na+]2+ and [4d-8Cl-+2PPi4-+2Na+]2+, the presence of 
the dimer [(4b-8Cl-+2PPi4-+Na+)2]2+ was clearly observed allowing to compare the isotope 
distribution with the predicted one (Figure 10). For the anthracene containing tetra-Zn(II) complex 4d 
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the corresponding dimer was also observed, but with much lower intensity not allowing to resolve 
experimentally the isotope distribution. 
   
(a) (b) (c) 
Figure 10: Isotope distribution for ions: (a) m/z=923 [(4c-4Cl-+PPi4-+Na+)2]2+, (b) m/z = 1036 [(4b-8Cl-+2PPi4-
+Na+)2 + Na+]3+ and (c) proposed structure of dimer [4b-8Cl-+2PPi4-]2. 
1.4 Concluding remarks 
We have obtained luminescent synthetic receptors based on 1, 3, 5-triazine bis-Zn(II)-cyclen 
binding sites and arenes by transition metal mediated cross coupling reactions. The synthesized 
complexes are rigid in structure and show excellent analyte response in buffered aqueous solution. 
Complexes 4b, 4c and 4d have high affinities for pyrophosphate and oligocarboxylates (Boc-D4-NH2, 
Boc-E4-NH2) anions with changes in emission response reaching one order of magnitude. Though the 
coordination geometry of Zn(II)-cyclen is different in comparison with Zn(II)-Dpa, the affinities for 
the target anions are comparable. Thus, our complexes can be considered as alternative probes for 
polyphosphates and polycarboxylates.  
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1.5  Experimental Section 
General methods and materials 
All reagent grade chemicals were used without purification unless otherwise specified. Phenyl boronic 
acid, benzene-1, 4-diboronic acid, phenyl acetylene, cyanuric chloride, ATP, ADP, O-phospho-L-
serine, phenyl phosphate were obtained from Aldrich and used as received.  
UV–visible absorption spectra were recorded using a Cary 50 Bio spectrophotometer and emission 
spectroscopy was performed using a Varian Cary Eclipse fluorescence spectrophotometer. 
Except for phenylboronic acid (2a) and benzene-1, 4-diboronic acid (2b), all other boronic 
acids (2c-2h) were synthesized following reported procedures. [25], [26] 
NMR Spectra 
NMR spectra were measured with Bruker Avance 600 (1H: 600.1 MHz, 13C: 150.1 MHz, T = 300 
K), Bruker Avance 400 (1H: 400.1 MHz, 13C: 100.6 MHz, T = 300 K), Bruker Avance 300 (1H: 
300.1 MHz, 13C: 75.5 MHz, T = 300 K). The chemical shifts are reported in δ [ppm] relative to 
external standards (solvent residual peak). The spectra were analysed by first order, the coupling S-1 
constants are given in Hertz [Hz]. Characterisation of the signals: s = singlet, d = doublet, t = triplet, q 
= quartet, m = multiplet, br = broad, dd = double doublet. Integration is determined as the relative 
number of atoms. The solvent used is reported for each spectrum. 
 
Mass Spectra 
Mass spectra were obtained with Varian CH-5 (EI), Finnigan MAT 95 (CI; FAB and FD), Finnigan 
MAT TSQ 7000 (ESI). Xenon serves as the ionisation gas for FAB. 
 
IR Spectra 
IR spectra were recorded with a Bio-Rad FTS 2000 MX FT-IR and Bio-Rad FT-IR FTS 155 
General procedure for the synthesis of complexes 4: To a mixture of Boc-protected bis-cyclen 
chloro-triazene 1 (100 mg, 0.1mmol) and Pd(PPh3)4 (10 mg, 0.012mmol, 12 mol %) in DME, the 
required aryl boronic acid 2 (1.5 eq. of monoboronic acid and 0.5 eq. of diboronic acid) was added, 
which was immediately followed by aqueous Na2CO3 (2M, 2ml). The mixture was refluxed for 48 h 
under N2 atmosphere. After cooling, the solvent was evaporated under reduced pressure to dryness. 
THF was added and the suspension was shortly placed in an ultra sonication bath. The mixture was 
then filtered, washed thoroughly with THF and the filtrate was evaporated under reduced pressure. 
The residue was purified by column chromatography on silica gel using ethyl acetate and petrol ether 
solvent mixture as eluent, to afford the pure products 3 as solids.  
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The obtained ligand 3 was Boc–deprotected with 14 equivalents of trifluoroacetic acid per 
Boc group and passed through a basic ion exchange column. The Boc–deprotected azamacrocycles, 
except in the case of 4d, were dissolved in acetonitrile, anhydrous ZnCl2 (2.5 eq. for 4a, 4c, 4e-4h and 
4.5 eq. for 4b, 4d) dissolved in methanol was slowly added to it leading to the formation of a white 
precipitate. For the synthesis of 4d, the Boc-deprotected 3d was dissolved in methanol/water (4:1) 
mixture, anhydrous ZnCl2 (4.5 eq.) dissolved in methanol was slowly added to it. The reaction 
mixture was refluxed overnight, which dissolved the precipitate. The hot solution is then decanted in a 
conical flask. Upon cooling a white precipitate is obtained, which was filtered and analyzed by NMR 
spectroscopy. The individual reaction and characterization details are described below. 
 
Compound 4a: The Boc-protected ligand 3a was obtained as a colorless solid (53 mg, 50%) (Rf 
=0.68, EE/PE 50:50).  It was then Boc deprotected using TFA yielding the free base (23 mg, 97%) 
followed by zinc-complexation (30 mg, 100%). 
3a: 1H NMR (300MHz, CDCl3) δ [ppm]: 1.44 (s, 54H, CH3-BOC), 3.41-3.91 (br, m, 32H, CH2-
cyclen), 8.441 (d, 2H, J = 6.9), 7.469 (t, 1H), 7.438 (t, 2H); 13C NMR  (75MHz, CDCl3) δ [ppm]: 27.5 
(+, CH3-BOC), 49.1, 49.7, 50.2 (-, CH2-cyclen), 76.5, 78.9 (Cquart, C-BOC), 156.4, 157.0 (Cquart, C=O 
BOC), 168.6 (Cquart, triazine-CAryl-N), 126.9, 127.430, 130.2, 135.5 (benzene). MS (ES-MS) 
(DCM/MeOH +10mM NH4OAc) m/z (%) = 1094 (100) (MH+). 
4a: 1H NMR (300 MHz, CDCl3) δ [ppm]: 8.492 (t, 2H), 7.512-7.623 (m, 3H), 4.433-4.508 (m, 2H), 
4.149 (br, s, 2H), 2.721-3.554 (m, 28H), 13C NMR (75 MHz, CDCl3) δ [ppm]: 42.4,  43.3, 44.5, 45.5, 
45.6, 46.4, 47.6, 47.9 (-, CH2-cyclen), 128.1, 128.5, 132.2, 132.4, 135.1, 135.3, 170.3, 170.8. - MS 
(ESI-MS) (DCM/MeOH +10mM NH4OAc) m/z (%) = 372.6 (100) (M4++2CH3COO-) 2+. M.P. 235-
238 °C; IR (ATR) [cm-1]: ~ = 3100, 2940,1350, 1154, 968, 820; UV (HEPES pH 7.4, 25mM): max 
(log ) = 224 nm (4.4) MF: [C25H43N11Zn2]4+4ClO4-. FW: 1026.25 g/mol. 
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Compound 4b: The Boc-protected compound 3b was obtained as a colorless solid (64 mg, 31%) (Rf 
=0.68, EE/PE 50:50). It was then Boc-deprotected using TFA (27 mg, 96%) followed by Zn-
complexation (41 mg, 100 %). 
3b:  1H NMR (300MHz, CDCl3) δ [ppm]: 1.391 (s, 108H, CH3-BOC), 3.370-3.594 (br, m, 64H, CH2-
cyclen), 8.368 (s, 4H); 13C NMR (300MHz, CDCl3) δ [ppm]: 28.52 (+, CH3-Boc), 50.24 (-, CH2-
cyclen), 79.91 (Cquart, C-Boc), 128.11, 156.62, 169.46. MS (ES-MS) (DCM/MeOH +10mM NH4OAc) 
m/z (%) = 1060 (100) (M+2H+) 2+, 1010 (50) (M+2H+-BOC) 2+, 2119.2 (10) (MH+) 
4b: 1H NMR (300MHz, DMSO-d6) δ [ppm]: 1.042-1.992 (br, m, 58H), 2.925 (br, 6H), 6.878 (s, 4H); 
13C NMR (75MHz, DMSO-d6) δ [ppm]: 44.2, 46.3, 129.5, 140.5, 168.9, 171.4; MS (ES-MS) 
(H2O/MeOH +10mM NH4OAc) m/z (%) = 490.7 (100) (M8++5CH3COO-) 3+. M.P.:255-257°C;   IR 
(ATR) [cm-1]: ~ = 3398, 2933, 1680, 1524, 1347, 1193, 1132, 1087, 971, 813, 723. – UV (HEPES 
pH 7.4, 25mM): max (log ) = 285 nm (4.530).MF: [C44H92N22Zn4]8+Cl8. – FW: 1474.50 g/mol. 
 
 
 
Compound 4c: The Boc-protected compound was obtained as a colorless solid (56mg, 50%) (Rf 
=0.68, EE/PE 50:50). It was then Boc deprotected using TFA. (25mg, 95%) followed by Zn-
complexation (36 mg, 100%). 
 
3c: 1H NMR (300MHz, CDCl3) δ [ppm]:1.451 (s, 54H, CH3-BOC), 3.440-3.661 (br, m, 32H, CH2-
cyclen), 7.316-7.439 (m, 4H), 7.903 (br, d, 2H), 8.003 (d, 2H), 8.445 (s, 1H); 13C NMR (75MHz, 
CDCl3) δ [ppm]: 22.88, 26.30, 26.87, 27.48, 28.43, 48.95, 49.99, 79.05, 123.93, 124.28, 125.17, 
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126.12, 127.31, 127.82, 130.27, 133.22; MS (ES-MS) (DCM/MeOH +10mM NH4OAc) m/z (%) = 
1023 (100) (M+2H+) 2+, 1199 (65) (MH+), 1053 (35) (M+2H+-BOC) 2+. 
4c: 1H NMR (300MHz, DMSO-d6) δ [ppm]: 2.647-3.231 (br, m, 32H), 4.249 (br, s, 2H), 4.815 (br, s, 
4H), 7.445-7.573 (m, 4H), 8.025 (d, 2H), 8.168 (d, 2H), 8.725 (s, 1H); 13C NMR(150MHz, DMSO-
d6) δ [ppm]: 30.6, 44.8, 46.8(CH2 Cyclen), 125.4, 126.2, 128.1, 130.7, 132.8, 133.1, (CH, aromatic), 
158.0, 169.2, 172.5, 173.0; MS (ES-MS) (H2O/MeOH +10mM NH4OAc) m/z (%) = 423.6 (100) 
(M4++2CH3COO-) 2+. M.P.: 274-282°C; IR (ATR) [cm-1]: ~ = 3090, 2943, 1345, 1087, 1130, 963, 
825; UV (HEPES pH 7.4, 25mM): max (log )=365 nm (3.9) MF:[C33H47N11Zn2]4+Cl4-. FW: 870.37 
g/mol. 
 
Compound 4d: The Boc-protected compound was obtained as a colorless solid (65mg, 30%) (Rf 
=0.68, EE/PE 50:50). It was then Boc deprotected using TFA. (12mg, 95%) followed by Zn-
complexation (18mg, 100%) 
3d:1H NMR (300MHz, CDCl3) δ [ppm]: 1.457 (s, 108H, CH3-Boc), 3441-3.653 (br, m, 64H, CH2-
cyclen), 7.283-7.317 (dd, 4H), 7.834-7.868 (br, 4H); 13C NMR (300MHz, CDCl3) δ [ppm]: 27.5 (+, 
CH3-Boc), 48.9 (-, CH2-cyclen), 79.0 (Cquart, C-Boc); MS (ES-MS) (DCM/MeOH +10mM NH4OAc) 
m/z (%) = 1110.6 (100) (M+2H+) 2+, 2220 (6) (MH+)  
4d: 1H NMR (300MHz, D2O) δ [ppm]: 2.667-2.965 (m, 46H), 2.987-3.011 (br, 3H), 3.192-3.337 (br, 
18H), 7.4921-7.953 (dd, 4H), 13C NMR  (150 MHz, D2O) δ [ppm]: 43.6, 44.8, 46.1, 47.6, 113.4, 
115.3, 117.2, 119.2, 169.8, 173.9; MS (ES-MS) (H2O/MeCN) m/z (%) = 355.0(M8++4Cl-) 4+(100), 
485.2 (M8++5Cl-)3+(50). M.P.: 292-296 °C; IR (ATR) [cm-1]: ~ = 3025, 2893, 1640, 1585, 1125, 
980, 720; UV (HEPES pH 7.4, 25mM): max (log ) = 370 nm (3.36) MF: [C52H84N22Zn4]8+Cl8–. FW: 
1562.52 g/mol. 
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Compound 4e: The Boc-protected compound was obtained as a colorless solid (62mg, 54%) (Rf 
=0.68, EE/PE 50:50). It was then Boc deprotected using TFA. (30mg, 96%) followed by Zn-
complexation (43mg, 100%) 
3e: 1H NMR (300MHz, CDCl3) δ [ppm]: 1.466(s, 54H, CH3-BOC), 3.150-3.896 (br, m, 32H, CH2-
cyclen), 8.015-8.216 (m, 7H), 8.571(br, d, 1H), 9.109 (br, s, 1H); 13C NMR  (75MHz, CDCl3) δ 
[ppm]: 50.3, 51.0, 80.1, 124.3, 124.7, 125.2, 125.4, 125.9, 127.3, 127.5, 128.3, 130.71, 131.2; MS 
(ES-MS) (DCM/MeOH +10mM NH4OAc) m/z (%) = 1223 (100) (MH+), 1022.9 (20) (MH+-2BOC) 
4e: 1H NMR (300MHz, CDCl3) δ [ppm]: 2.730-2.941 (br, m, 28H), 3.472 (br, s, 2H), 4.391(br, s, 
4H), 4.935 (br, d, 4H), 8.150 (t, 1H), 8.290-8.421 (m, 6H), 8.593 (d, 1H), 9.042 (d, 1H); 13C NMR 
(75MHz, CDCl3) δ [ppm]: 43.9, 45.0, 46.3, 47.3, 123.6, 123.9, 124.5, 125.4, 125.6, 126.0, 126.6, 
127.3, 128.2, 128.7, 128.8, 130.1, 130.7, 132.2, 132.2, 169.3, 172.7; MS (ES-MS) (H2O/MeOH 
+10mM NH4OAc) m/z (%) = 434.8 (100) (M4++2CH3COO-) 2+. M.P.: 285-287 °C; IR (ATR) [cm-1]: 
~ = 3125, 2890, 1650, 1545, 1175, 980, 880, 715; UV (HEPES pH 7.4, 25mM): max (log ) = 350 
nm (4.16) MF: [C35H47N11Zn2]4+Cl4–. FW: 894.39 g/mol. 
 
Compound 4f: The Boc-protected compound was obtained as a colorless solid (83mg, 78%) (Rf 
=0.58, EE/PE 50:50). It was then Boc deprotected using TFA. (37mg, 97%) followed by Zn-
complexation (72mg, 100%) 
3f: 1H NMR (300MHz, CDCl3) δ [ppm]: 1.478 (s, 54H, CH3-BOC), 2.84 (t, 2H, CH2), 3.12 (t, 2H, 
CH2), 3.31-3.87 (br, m, 32H, CH2-cyclen), 7.22-7.26 (m, 5H, aromatic protons); 13C NMR (75MHz, 
CDCl3) δ [ppm]: 21.1 (CH2), 28.4, 28.5 2 (CH3-Boc), 41.1 (CH2), 50.1 (CH2- cyclen), 79.86 (Cquart, C-
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Boc), 125.5, 128.2 (aromatic C), 144.2 (Cquart, aromatic C), 176.7 (Cquart, triazine); MS (ES-MS) 
(DCM/MeOH +10mM NH4OAc) m/z (%) = 1126.7 (100) (MH+), 1164.6 (40) (MK+). 
4f: 1H NMR  (300MHz, CDCl3) δ [ppm] = 2.84 (t, 2H, CH2), 3.12 (t, 2H, CH2), 3.29-3.55 (br, m, 
32H, CH2-cyclen), 7.22-7.26 (m, 5H, aromatic protons); 13C NMR (75MHz, CDCl3) δ [ppm]: 21.3 
(CH2), 41.1 (CH2), 50.1 (CH2- cyclen), 79.8 (Cquart, C-Boc), 125.5, 128.2 (aromatic C), 144.2 (Cquart, 
aromatic C), 176.7 (Cquart, triazine); MS (ES-MS) (H2O/MeOH +10mM NH4OAc) m/z (%) = 386.5 
(100) (M4++2CH3COO-) 2+. M.P.:290-293°C; IR (ATR) [cm-1]: ~ = 3290, 2942, 2971, 2863, 1645, 
1470, 1385,980, 824, 728; MF: [C27H47N11Zn2]4+Cl4–. FW: 798.3 g/mol. 
 
Compound 4g: The Boc-protected compound was obtained as a colorless solid (50mg, 47%) (Rf 
=0.71, EE/PE 50:50). It was then Boc deprotected using TFA. (23mg, 96%) followed by Zn-
complexation (40mg, 100%) 
3g: 1H NMR (300MHz, CDCl3) δ [ppm]: 1.445(s, 54H, CH3-BOC), 3.428-4.085 (br, m, 32H, CH2-
cyclen), 6.839(d, CH-ethylene, J=15.9), 7.338-7.358 (m, 3H, aromatic protons), 7.568 (d, 2H, 
aromatic protons, J=7.2), 7.959(d, 1H, CH-ethylene, J=15.9); 13C NMR (75MHz, CDCl3) δ [ppm]: 
28.3, 28.6 (CH3-Boc), 49.1, (CH2- cyclen), 78.8 (Cquart, C-Boc), 126.6, (C=C), 127.6, 127.9 (aromatic 
C), 135.0(C=C), 168.9 (Cquart, triazine); MS (ES-MS) (DCM/MeOH +10mM NH4OAc) m/z (%) = 
1124.5 (100) (MH+). 
4g: 1H NMR  (300MHz, CDCl3) δ [ppm] = 2.67-3.76 (br, m, 38 H), 6.35(d, CH-ethylene), 7.18-
7.55(m, aromatic protons), 7.79(d, CH-ethylene); 13C NMR (75MHz, CDCl3) δ [ppm]: 43.9, 45.0, 
46.3, 47.3, 123.6, 123.9, 124.4, 125.4, 125.6, 125.9, 126.6, 127.3, 128.2, 128.7, 128.8, 130.1, 130.7, 
132.2, 132.2, 169.2, 172.7; MS (ES-MS) (H2O/MeOH +10mM NH4OAc) m/z (%) = 385.5 (100) 
(M4++2CH3COO-) 2+, IR (ATR) [cm-1]: ~ = 3385, 3083, 2966, 2896, 1680,1644, 1525, 1465, 1182, 
965, 812, 720; UV (HEPES pH 7.4, 25mM): max (log ) = 220nm (4.10) MF: [C27H45N11Zn2]4+Cl4–. 
FW: 796.29 g/mol. 
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Compound 4h: The Boc-protected compound was obtained as a colorless solid (56mg, 52%) (Rf 
=0.68, EE/PE 50:50). It was then Boc deprotected using TFA. (24mg, 92%) followed by Zn-
complexation (48mg, 100%) 
3h: 1H NMR (300MHz, CDCl3) δ [ppm]: 0.87 (t, 3H, CH3), 1.455 (s, 54H, CH3-BOC), 1.576-1.711 
(m, 10H, CH2), 2.458 (t, 2H, CH2), 3.22-3.76 (br, m, 32H, CH2-cyclen; 13C NMR (75MHz, CDCl3) δ 
[ppm]: 28.5, 28.7 (CH3-Boc), 49.5 (CH2- cyclen), 78.8 (Cquart, C-Boc), MS (ES-MS) (DCM/MeOH 
+10mM NH4OAc) m/z (%) = 1120.9 (100) (MH+). 
4h: 1H NMR (300MHz, dmso-d6) δ [ppm]: 0.86 (t, 3H, CH3-alkyl chain) 1.26 (br, s, 8H), 1.75 (s, 
7H), 2.1 (s, 6H), 2.89 (br, m, 16H), 3.4 (s, 13H); 13C NMR (75MHz, dmso-d6) δ [ppm]: 13.7 (CH3-
alkyl chain), 17.8, 21.8, 22.1, 22.2, 26.2, 28.3 (CH2-alkyl chain), 30.9, 39.1, MS (ES-MS) 
(H2O/MeOH +10mM NH4OAc) m/z (%) = 383.6 (100) (M4++2CH3COO-) 2+. IR (ATR) [cm-1]: ~ = 
2921, 2852, 1693, 1561, 1525, 1465, 1420, 1346, 1282, 1085, 812; MF: [C26H53N11Zn2]4+Cl4–. FW: 
792.35 g/mol 
 
Synthesis of Compound 5: In a two necked flask, Boc-protected bis-cyclen chloro-triazene 1 (0.2 g, 
0.19 mmol), Pd/C (10%, Fluka), PPh3, CuI in 1/0.04/0.16/0.04 molar ratio, were placed under 
nitrogen atmosphere along with DIPEA (1.5 ml) as the suitable base. After accurately purging with 
nitrogen, a solution of phenyl acetylene (0.05 ml, 0.48 mmol) in CH3CN was added, the temperature 
was raised and the mixture was kept under vigorous stirring for overnight. After cooling and filtering 
the mixture on a short package of celite, the solution was evaporated under reduced pressure. The 
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crude reaction mixture was purified by column chromatography using 40% ethyl acetate in petrol 
ether as the eluent to get the pure product 5 (51%).  
1H NMR (300MHz, CDCl3) δ [ppm]: 1.45 (s, 54H, CH3-BOC), 3.24-4.00 (br, m, 32H, CH2-cyclen, 
7.5-7.57 (dd, 2H, benzene ring), 7.29-7.43 (m, br, 3H, benzene ring); 13C NMR (75MHz, CDCl3) δ 
[ppm]: 27.5, 48.9, 87.6, 120.8, 127.2, 128.3, 131.4, 158.0; MS (ES-MS) (DCM/MeOH +10mM 
NH4OAc) m/z (%) = 1122.8 (100) (MH+); IR (ATR) [cm-1]: ~ = 3385, 3083, 2966, 2896, 2250, 
1680, 1512, 1465, 1182, 965, 812, MF: C57H91N11O12, FW: 1122.4 g/mol 
 
X-ray structure determination 
Crystal data for C33H47Cl2N11Zn2·CH3OH·ZnCl4, CCDC 808617 M= 1038.73 g/mol, monoclinic, P 
21/c, a= 13.33784(16) Å, b= 29.7188(4) Å, c= 10.88517(13) Å, α = 90°, β = 94.0245(11)°, γ = 90°, 
V= 4304.07(9) Å3, Z=4, 18752 reflections measured, 8828 independent (Rint = 0.0208), which were 
used in all calculations. The final wR2 was 0.0972 (all data). Intensity data were collected with a 
graphite-monochromated Mo-Ka radiation (λ = 1.54184Å) at 123K on a Goniometer Xcalibur, 
detector: Ruby (Gemini ultra Mo). Data collection, structure solution and refinement used programs: 
SHELXL,[27] R1 is calculated for observed data and wR2 for all data. 
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1.6  Supporting data 
1H and 13C spectra of synthesized compounds 
 
 
1H-NMR spectrum of compound 3a (300 MHz, CDCl3) 
 
 
1H-NMR spectrum of compound 4a (300 MHz, CD3CN) 
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1H-NMR spectrum of compound 3b (300 MHz, CDCl3) 
 
 
 
1H-NMR spectrum of compound 4b (300 MHz, CD3CN) 
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1H-NMR spectrum of compound 3c (300 MHz, CDCl3) 
 
 
 
1H-NMR spectrum of compound 4c (300 MHz, D2O) 
 
1. Rigid Luminescent bis-Zinc(II)-bis-Cyclen Complexes for the Detection of Phosphate Anions and non-
covalent Protein Labeling in Aqueous Solution    
 
 
  27 
 
1H-NMR spectrum of compound 3d (300 MHz, CDCl3) 
 
 
 
1H-NMR spectrum of compound 4d (300 MHz, CD3OD) 
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1H-NMR spectrum of compound 3f (300 MHz, CDCl3) 
 
 
 
1H-NMR spectrum of compound 3g (300 MHz, CDCl3) 
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1H-NMR spectrum of compound 4h (300 MHz, (CD3)2SO) 
 
 
 
1H-NMR spectrum of compound 5 (300 MHz, (CDCl3) 
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13C-NMR spectrum of compound 3a (75 MHz, CDCl3) 
 
 
13C-NMR spectrum of compound 3c (75 MHz, CDCl3) 
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13C-NMR spectrum of compound 3d (75 MHz, CDCl3) 
 
 
13C-NMR spectrum of compound 5 (75 MHz, CDCl3) 
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The emission titration data analysis and molecular modeling studies 
 
Figure11: HOMO of complex 4b (left) and 4d (right). In case of 4b benzene and triazine moieties are in plane, 
while in case of 4d plane of anthracene is found to be orthogonal to the plane of triazine units. All models were 
obtained by molecular modeling using the program package Spartan `06 (Wavefunction Inc.) by energy 
minimization (DFT, B3LYP, 6-31G*) 
  
Figure12: left: Emission titration of 4e with pyrophosphate in HEPES buffer solution. [4e] = 50 µM, [PPi] = 2.5 
mM, right: HOMO of complex 4e in presence of pyrophosphate. The model was obtained by molecular 
modeling using the program package Spartan `06 (Wavefunction Inc.) by energy minimization (DFT, B3LYP, 
6-31G*) 
Mass Spectroscopic studies 
ESI mass spectroscopic studies of the complexes were measured on a Thermo Quest Finnigan TSQ 
7000 mass spectrometer. The solutions of interest were prepared as 10-4M solution of a complex with 
a guest in 1:2 stoichiometry in water-acetonitrile mixture and one drop of triethylamine. 
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Figure 13: ESI of a mixture of 4d (Zn4anthr) and D4 tag. 
 
 
 
 
Figure14: ESI of a mixture of 4b (Zn4benz) and D4 tag. 
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Figure15: ESI of a mixture of 4d (Zn4anthr) and sodium pyrophosphate (PPi). 
 
 
Figure 16: ESI in the area m/z=1080-1114 of a mixture of 4d (Zn4anthr) and sodium pyrophosphate (PPi) 
showing the peaks which correspond to the [2+4] complex. The difference between peaks m/z=M(Na+)/3. 
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Figure 17: ESI of a mixture of 4b (Zn4benz) and sodium pyrophosphate (PPi). 
 
 
 
 
 
Figure 18: ESI in the area m/z=1024-1048 of a mixture of 4b (Zn4benz) and sodium pyrophosphate (PPi) 
showing the peaks which corresponds the [2+4] complex. The difference between peaks is m/z=M(Na+)/3 
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Figure 19: ESI spectra of a mixture of 4c (Zn2antr) and sodium pyrophosphate (PPi) 
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Chapter 2 
Rigid Amphiphilic Molecular receptors, Bioconjugates 
and Radiopharmaceuticals based on Metal-cyclen 
complexes via Click chemistry 
 
 
 
 
 
 
 
 
 
 
‘‘Click chemistry-the reinvigoration of an old style of organic synthesis’’ 
 
-Kolb, Finn and Sharpless in 2001[1] 
2. Rigid Amphiphilic Molecular receptors, Bioconjugates and Radiopharmaceuticals based on Metal-
cyclen complexes via Click chemistry 
 
 
  40 
2.1  General Introduction  
2.1.1 The “Click” Philosophy 
Since their debut, click chemistry and related procedures have stimulated many different 
research fields. In 2001, Kolb, Finn and Sharpless published one important review coining the term 
“Click Chemistry” which addresses a set of powerful, highly reliable, and selective reactions for the 
rapid synthesis of useful new compounds and combinatorial libraries.[2] The click reactions are 
governed by kinetic control and are highly reliable and selective processes. The set of stringent 
criteria that must be fulfilled in the context of click chemistry, as defined by Sharpless et al. are 
reactions that “ are modular, wide in scope, high yielding, create only inoffensive by-products (that 
can be removed without chromatography), are stereospecific, simple to perform and that require 
benign or easily removed solvent”.[3] 
Although the criteria drawn for the “Click Chemistry” status are highly subjective, several 
processes or reactions have been identified which fit to the concept: Cycloaddition reactions (eg. 
Huisgen 1,3–dipolar cycloadditon reactions[4], Diels-Alder reactions and inverse electron demand 
Diels-Alder reactions);[1] carbonyl chemistry of the non-Aldol type (eg. formations of ureas, thioureas, 
hydrazones, oxime ethers, amides, aromatic heterocycles etc);[3] nucleophilic ring opening reactions 
(eg. the openings of strained heterocyclic electrophiles, such as aziridines, epoxides, cyclic sulfates, 
aziridinium ions, episulfonium ions, etc);[1] addition reactions to carbon-carbon multiple bonds (eg. 
epoxidations, aziridinations, dihydroxylations, sulfenyl halide additions, nitrosyl halide additions, and 
certain Michael additions)[1, 3] are some of the major processes that can be mentioned. 
 
 
Scheme1: The CuAAC results in 1,4- regioisomer as exclusive product while thermal Huisgen 1,3-
Cycloaddition results in a mixture of both 1,4 and 1,5- regioisomers often in 1:1 ratio.  
 
 Among all these processes, Huisgen 1,3-dipolar cycloaddition reaction has gained a special 
place. The ease of synthesis of the alkyne and azide functionalities, coupled with their kinetic stability 
and tolerance to a wide variety of functional groups and reaction conditions, make these 
complementary coupling partners particularly attractive.[5] Above this, the dramatic rate acceleration 
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of the azide–alkyne coupling event under copper (I) catalysis[6] and the selectivity for the 1,4-
disubstituted 1,2,3-triazole (anti-1,2,3-triazole)[7], the copper catalyzed version (CuAAC) has been the 
most popular and widely used and often referred simply as ‘The Click reaction’.  
 
 
 
Scheme2: Outline of a plausible mechanisms for the Cu(I) catalyzed reaction between organic azides and 
terminal alkynes [adapted from the quoted reference][8] 
 
2.1.2 The Click reaction: An efficient strategy for bioconjugations 
The term ‘bioconjugation’ comprehend a broad interdisciplinary area developed at the 
interface between molecular biology and chemistry.[9] Bioconjugation techniques mainly involve the 
covalent attachment of biological molecules to non-biological molecules to form a novel complex 
having the combined properties of all the individual components and its integration in functional 
devices.[10] 
Bioorthogonal conjugations via the click reaction 
Bioconjugation techniques are of general interest for both biologists and chemists. Over the  
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years several efficient bioconjugation techniques have been developed to attach fluorescent probes, 
affinity tags, or isotope labels to different biomolecules. Many different coupling strategies such as 
thiol-maleimide, amine-activated ester coupling, have been used repeatedly to decorate biomolecules 
or cell surface labeling in vitro.[11] However for in vivo labeling of biomolecules, the couplings 
partners have to react efficiently and selectively even in presence of a vast variety of accessible 
reactive moieties, which are present in complex biological medium. To handle the problems of in vivo 
labeling, concept of bioorthogonal chemistry has been developed that deals with bioorthogonal 
chemical reporters, which are defined as “non-native, non-perturbing chemical handles that can be 
modified in living systems through highly selective reactions with exogenously delivered probes.”[12] 
Several site-specific, bioorthogonal, conjugation techniques have been developed to overcome the 
problems encountered with in vivo labeling and one of the most frequently used techniques is the 
click reaction.[1, 13] The reactant partners of the click reaction, azide and alkyne, both are highly 
energetic functional groups with relatively narrow distributions of reactivity[13c] and the reaction can 
proceed irreversibly in water at neutral pH and biocompatible temperatures (25–37°C) without any 
cytotoxic reagents or byproducts. Azide functionality is particularly interesting in this case, as it is 
absent in almost all the known natural compounds and despite a high intrinsic reactivity, azides allow 
selective ligation with a limited number of reactive partners.[5] This property of bioorthogonality 
provides extreme selectivity for bringing together azide and alkyne derivatives to form triazoles even 
in complex biological samples.[9] Also it is noteworthy that azide and alkyne groups are easy to 
introduce into organic compounds by both nucleophilic and electrophilic processes. Hence these can 
be incorporated into biological molecules by organic synthesis and chemical conjugation (or via 
biosynthetic pathways using predesigned precursors[14]).  
The possibility of using CuAAC for bioconjugation was first demonstrated by Meldal et al in 
their publication in 2002, where they have reported synthesis of peptidotriazoles by solid phase 
synthesis.[15] Following this landmark report, numerous functional and reporter groups are introduced 
into biomolecules such as peptide and proteins for DNA labeling and cell surface labeling.[16] 
Sharpless et al could successfully demonstrate bioorthogonality of CuAAC by labeling of Cowpea 
mosaic virus (CPMV) (a biomolecular scaffold with a structurally rigid assembly of 60 identical 
copies of a two-protein asymmetric unit around a single-stranded RNA genome) with fluorescein in 
quantitative yield.[13c]  
Similarly some other notable bioorthogonal conjugations via click chemistry are: cell surface 
labeling of Escherichia coli via copper catalyzed click reaction [Link and Tirrell, 2003][16], total solid-
phase synthesis of marine cyclodepsipeptide IB-01212 [Cruz et al, 2006][17], functionalization of 
modified DNA [Carell et al, 2006][18].  
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Figure 1:  Labeling of Cowpea mosaic virus (CPMV) with fluorescein via click reaction [adapted from the 
quoted reference][13c] 
The Click Reaction in Radiopharmaceutical Chemistry 
 Currently application of click chemistry receives growing interest in the field in 
radiopharmacy. The 1,2,3-triazole moiety was found to improve the pharmacokinetic properties of 
certain radiopharmaceuticals[19] and there are several reports based on application of click chemistry 
for radiollabeling of peptidic compounds or new radiotracers. Since several noninvasive molecular 
imaging techniques such as positron emission tomography (PET), single-photon emission computed 
tomography (SPECT) emerge as highly sensitive imaging method for in vivo studies,  radiolabeling of 
biologically active molecules has become an important tool to assess novel drug candidates. There are 
several reports where the click reaction was used as an efficient strategy to synthesize radiolabeled 
(18F, 11C) peptides as imaging agents for PET.[20] 
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Figure 2: Some of the radiopharmaceuticals synthesized via click chemistry [21] 
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2.2  Outline of the Chapter 
In this chapter the use of click chemistry for the design and the synthesis of bioconjugates and 
radiopharmaceuticals and also of modified rigid amphiphilic molecular receptors based on metal-
cyclen complexes are summarized. We have synthesized alkynes of different biologically important 
molecules such as cholesterol, biotin and used Cu(I) mediated click reaction to attach these alkynes to 
the azide of bis-cyclen by forming a 1,2,3-triazole. The applications or the potential applications of 
the synthesized bioconjugate and radiopharmaceuticals are discussed. 
We also report the design and the synthesis of a modified rigid amphiphilic molecular receptor 
based on metal-cyclen complexes via click reaction for potential application in a template guided 
cooperative self-assembly of nucleotides at fabricated interfaces. 
 
2.3 Design and synthesis of bioconjugates based on a Zn(II)-bis-cyclen complex: 
Introduction to potential applications, results and discussions 
2.3.1 Synthesis of bis-cyclen azide 
 
 The azide functionality used for the click reaction is a modification of bis-cyclen and it was 
synthesized as shown in Scheme 3 
 
 
 
 
Scheme 3: Synthesis of bis-cyclen-azide (a) NaN3 (1eq), acetone/water (1:1), 5 min, rt [yield: 15%], (b) K2CO3, 
acetone, 56°C, 12h [yield: 20%] 
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2.3.2 Biotin bioconjugate of a Zn(II)-bis-cyclen complex for potential applications in 
activity based proteomics1 
2.3.2.1  Introduction and aim of the project 
Over last two decades, activity based protein profiling (ABPP); originally invented by James 
C. Powers (Georgia Tech, Atlanta) in 1990;[22] has proven to be an attractive toolkit for functional 
proteomic techniques. This technique uses chemically designed small activity probes (ABP) to tag, 
enrich, and isolate, distinct sets of proteins based on their enzymatic activity. The probes can be 
modified chemically to interact with a defined protein site and a complex mixture of proteins can be 
selectively enriched via a reactive activity probe. ABPs function as highly specific, mechanism-based 
reagents that provide a direct readout of enzymatic activity within complex proteomes. Modification 
of protein targets by an ABP facilitates their purification and isolation.[23] The activity probes typically 
consist of two elements: a reactive group (RG) and a tag. Additionally, some probes may contain a 
binding group which enhances selectivity. The reactive group is designed to interact with a specific 
class of protein and the reporter tag to signal the interaction or binding (eg. fluorescence, affinity, 
isotope labeled tags).  
 Here, we report the design and synthesis of a biotin labeled Zn(II)-bis-cyclen complex as an 
activity probe (ABP) for profiling of phosphorylated proteins. These can also be considered as a 
chemically modified potential phosphospecific artificial antibody. Protein phosphorylation is 
recognized to play a crucial role in the regulation of cell growth and development.[24] Also 
phosphorylation plays an important role in signaling pathways.[25] Therefore it is important to detect 
the changes in the phosphorylation state of proteins. Zn(II)-bis-cyclen complex is known for its 
affinity towards phospho anions. Hence we have considered coupling of Zn(II)-bis-cyclen with a 
reporter tag to design an activity probe for phosphorylated proteins.  Biotin is used as the reporter tag 
for the synthesized probe.   
 
2.3.2.2  Design and synthesis of biotin bioconjugate of Zn(II)-bis-cyclen complex 
The biotinylated Zn(II) bis-cyclen complex was synthesized by click reaction between 
biotinylated acetylene and bis cyclene azide as shown in Scheme 4.  
                                                            
1 The biotin bioconjugate of Zn(II)-bis-cyclen was synthesized by Mouchumi Bhuyan. The gel phase studies 
were done by Thomas Zanni and Mouchumi Bhuyan. We are thankful to Dr. Sabine Amslinger for helpful 
discussions and collaboration. 
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Scheme 4: Synthesis of Biotin bioconjugate of Zn(II)-bis-cyclen complex (a) Biotin acetylene, CuSO4, sodium 
ascorbate, TBTA, DMF, rt, 12h [yield: 90%]; (b) TFA, DCM, 4h,  basic ion exchanger resin [yield: 
quantitative]; (c) Zn(ClO4)2, MeOH/MeCN, reflux, o/n [yield: 99%]. Counter ions of the complexes to yield a 
neutral complex are not shown for clarity.  
The acetylene of biotin was synthesized following a reported procedure. Detailed 
experimental procedures and characterization are reported in the experimental and supporting data 
section. 
 
2.3.2.3  Selective recognition of phosphorylated protein in gel phase 
To evaluate the selectivity of our probe towards phosphorylated proteins, western blot 
technique has been carried out using a nitrocellulose membrane. Phopshorylated bovine -casein, 
dephosphorylated -casein, ovalbumin and bovine serum albumin were used as protein samples. We 
have used horseradish peroxidase conjugated streptavidin to detect the biotinylated Zn(II) complex 
bound to the protein in the membrane and commercially available “Thermo Scientific SuperSignal 
West Pico chemiluminescent substrate” as an enhanced chemiluminescent (ECL) substrate for 
horseradish peroxidase (HRP) enzyme. To minimise the nonspecific interaction of the horseradish 
peroxidase conjugated streptavidin with the membrane, we have used BSA as a blocking buffer. 
Western blot technique showed that our probe detects phosphorylated casein and also 70% 
dephosphorylated casein while there was no signal for ovalbumin (Figure 2). Although ovalbumin has 
two phosphorylated sites, these may be not accessible by our probe due to steric reasons. These 
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preliminary studies encourage further investigations using a wider range of phosphorylated and non-
phosphorylated proteins. 
 
        
 
Figure 2: Gel phase studies with probe 6 using ovalbumin and ɑ-casein. [Left] Coomassie blue stained 
electrophoretic gel for ovalbumin, phosphorylated ɑ-casein and 70% dephosphorylated ɑ-casein; [Right] 
Western blot studies for ovalbumin, phosphorylated ɑ-casein and 70% dephosphorylated ɑ-casein [each lane 
contains 11µg of protein, concentration of the biotinylated Zn(II) complex is 10−6 M, concentration of 
horseradish peroxidase conjugated streptavidin is 0.2 µg/ml] 
 
2.3.2.4 Concluding remarks 
In conclusions we have reported the synthesis of a biotin bioconjugate of Zn(II)-bis-cyclen . 
The presence of the biotin moiety on the probe can be exploited for the enrichment and profiling of 
phosphorylated proteins. Preliminary western blot studies using phosphorylated casein and ovalbumin 
show the feasibility of the concept using biotinylated Zn(II) complex as a probe for activity based 
profiling of phosphorylated proteins. Further investigations on a wider range on proteins are under 
progress. 
 
2.3.3 Modified cyclen based precursor for potential radiopharmaceuticals for Positron 
Emission Tomography (PET)2 
2.3.3.1 Introduction and aim of the project  
Positron emission tomography (PET) is a nuclear medicine imaging technique that produces a 
three-dimensional image or picture of functional processes in the body. It deals with detection of pairs 
of gamma rays emitted indirectly by a positron-emitting radionuclide (tracer), which is introduced 
into the body on a biologically active molecule. A majority of PET radiopharmaceuticals for clinical 
and research applications are labeled commonly with four radionuclides: 15O, 13N, 11C and 18F. 
                                                            
2 This project is in progress in collaboration with Department of Chemistry and Pharmacy, Friedrich-Alexander 
University Erlangen, Germany. The synthetic part reported here is done at university of Regensburg by 
Mouchumi Bhuyan. 
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However, a number of metal radionuclides such as 55Co, 44Sc, 62Cu, 68Ga, 66Ga have also been studied. 
Among these, the use of gallium radionuclides in nuclear medicine dates back to the late 1940s[26] and 
it has three radioisotopes of interest for medical imaging, 67Ga (t1/2 = 3.25 days), 66Ga (t1/2 = 9.5 h) and 
68Ga (t1/2 = 68min). 68Ga is one very attractive radionuclide as it can be generated in situ easily, fast 
and cost effective way by using 68Ga/68Ge generator and leading to a minimum loss of activity.[27] 
There are two primary requirements for using gallium complexes as radiopharmaceuticals: 
first, the gallium complexes must resist hydrolysis at physiological pH [Ga(OH)3, the primary product 
of hydrolysis of a gallium complex is insoluble at physiological pH until [Ga(OH)4]− is formed at a 
higher pH (pH 9)]; second, the used gallium complexes should be more stable than the Ga(III)-
transferrin complex.[28] The ionic radii, ionization potential and coordination environment of Ga3+ is 
similar to that of Fe3+. Hence gallium complexes used as radiopharmaceuticals must be stable enough 
to avoid trans-chelation of Ga3+ to various iron binding proteins, particularly transferrin, which has 
two binding sites. These special requirements made it crucial to design polydentate ligands for Ga3+ 
and typically these are hexadentate. 
For in vivo cancer detection or for tracing tumour or neoplastic cells, peptides are gaining 
much attention as excellent tissue specific uptake can be achieved. Peptides can be modified and 
labeled chemically. Although among the radiolabeled peptides, 13F and 11C are commonly used 
radionuclides, there are some reports of radiolabeling of peptides with metallic radionuclides. 
Recently, Prante et al reported synthesis of 68Ga-amino acid conjugate and could successfully show its 
potential application as tumour tracer for PET.[29] As an extension to this idea, we (in collaboration 
with Department of Chemistry and Pharmacy, Friedrich-Alexander University Erlangen, Germany) 
developed a cyclen based 68Ga-peptide conjugate for potential applications as radiopharmaceutical. 
The challenge in preparing (radio)metal containing amino acids or peptides with retained biological 
activity is to develop an appropriate synthetic strategy.[29] We considered using the bioorthogonal and 
robust click reaction for the synthesis of the intended radiopharmaceuticals. We synthesised bis azide 
of cyclen based 68Ga chelate, which can be attached to the target peptides by using the click reaction. 
The rationale behind the synthesis of a bis-azide is to increase the intramolecular peptide 
concentration of the compounds, while maintaining the overall molecular weight in a reasonable 
range. 
2.3.3.2  Synthesis of precursor for potential Radiopharmaceuticals for Positron 
Emission Tomography (PET) 
The cyclen based bis azide for 68Ga-peptide conjugate was synthesized as shown in Scheme 5.  
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Scheme 5: Synthesis of precursor for potential Radiopharmaceuticals for positron emission tomography (PET) 
(a) NaN3(2eq), acetone/water(1:1), 10 min, rt [yield: 30%]; (b) benzyl bromoacetate, NaHCO3, MeCN, reflux, 
12h [yield: 45%]; (c) K2CO3, acetone, reflux, 8h [yield: 30%]; (d) terminal acetylene of desired peptide, Cu(I), 
base; (e) H2, Pd/C, solvent; (f) metal complexation with 68Ga salt [(d), (e) and (f) steps to be carried out in 
Department of Chemistry and Pharmacy, Friedrich-Alexander University Erlangen, Germany] 
Detailed experimental procedures and characterization are reported in the experimental and 
supporting data section. 
2.3.3.3 Concluding remarks 
We have designed and synthesized precursor for 68Ga based potential radiopharmaceuticals 
for Positron Emission Tomography (PET). Further synthetic development and investigations of the 
applicability of the synthesized complex as radiopharmaceutical are in progress. 
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2.3.4 Design and synthesis of rigid amphiphilic modified Zn(II)-cyclen based receptors 
for a template guided cooperative self-assembly of nucleotides at interfaces3 
2.3.4.1 Introduction and aim of the project 
Multivalent interactions based on non-covalent bonds, such as hydrogen bonding and metal-
ligand coordination, as well as  stacking, hydrophobic, ionic, and van der Waals forces are 
essential ingredients in the mediation of biological processes, as well as in the construction of 
complex (super)structures for materials applications.[30] Such weak interactions (bond energy 2-20 
kcal mol−1) play a key role in fundamental biological processes, such as protein folding or the 
expression and transfer of genetic information. Reversible formation of multiple hydrogen bonding is 
one of the most widely studied classes of non-covalent interactions in supramolecular chemistry, 
mainly because, the existence of H-bonds has long been regarded to play a crucial role in many 
biologically relevant processes, such as recognition between DNA base pairs, ligand-binding to 
receptor sites, enzyme catalysis, and α-helix or β-sheet formation.[31]  
Tailoring molecular organization is one of the final goals of supra molecular chemistry and is 
essential for the design of molecular devices.[32] In 1991, Kurihara et al reported for the first time the 
formation of two-dimensional arrangement of molecules at the air-water interface on a Langmuir-
Blodgett (LB) trough. They showed arrangement of nucleic acid bases at the air water interface, 
where the hydrogen bonding took place in the water phase and an amphiphilic diaminotriazine was 
able to selectively bind nucleosides and nucleic acid bases.[33] Over the last two decades, several 
strategies were reported using nucleic acid base pairing as a basis for planar molecular-recognition 
systems. Most of these reports focused on self-assembled monolayers (SAMs) or Langmuir 
monolayers that are formed from compounds bearing nucleobases or their synthetic analogues. 
However, both techniques individually have some limitations. Although LB is a well developed 
method, its practical applicability is severely limited and due to steric hindrance and phase separation 
of monolayer constituents, SAM based methods are not suitable for lateral tailoring of molecular 
recognition and also it is difficult to precisely control the size and distribution of the SAMs because 
the structure is determined by the interplay of the kinetics and thermodynamics of the self-assembly 
process.[32, 34] Langmuir-Blodgett (LB) monolayer technique in combination with the SAM-based 
approach can overcome the steric limitation of SAM. This combined approach was reported 
previously from our group. This technique showed fabrication of double layers modified by 
amphiphilic Zn(II)-cyclen complexes from self assembled monolayers and LB films and this double 
                                                            
3 The rigid amphiphilic Zn(II)-bis-cyclen receptors were synthesized at University of Regensburg by Mouchumi 
Bhuyan. The investigations at interfaces are in progress at the Institute of Physical Chemistry and 
Electrochemistry of the Russian Academy of Sciences in Moscow in the group of Prof. M. A. Kalinina. 
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layer could act as a 2D synthetic template for cooperative self-assembly of adenosine and uridine 
nucleotides.[34a] 
 
 
 
Figure 2: Schematic representation of the proposed mechanism of the stepwise self-assembly of complementary 
nucleotides on a SAM-Zn(II)-BC template [adapted from the quoted reference][34a] 
 
To expand the scope of this methodology and to extend the cooperativity, we considered to 
synthesize a rigid modified Zn(II)-tetra-cyclen based amphiphilic receptor and a cholesterol 
bioconjugate of a Zn(II)-bis-cyclen complex for template guided cooperative self-assembly of 
nucleotides at interfaces.  
 
2.3.4.2 Design and synthesis of rigid Zn(II)-bis-cyclen based amphiphilic receptors 
The rigid modified amphiphilic Zn(II)-bis-cyclen systems that were designed and synthesized 
for self assembled monolayer formation are shown in Figure 3. 
A monolayer based on Amp-1 may lead to the formation of an arrangement of four different 
nucleosides by stepwise self-assembly of complementary nucleotides. Again, cholesterol has a long 
hydrophobic steroid chain, which makes it a suitable candidate to assemble on the hydrophobic 
surface. Also, cholesterol, a sterol, is an essential component of cell membranes and some of the 
hormones and is known to alter several properties of lipid bilayers as it influences the permeability 
and fluidity of membranes.[35] Incorporation of cholesterol into Zn(II)-bis-cyclen (Amp-2) may lead to 
a modification of the response of the prepared layers to substrates or change their stability. 
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Figure 3: Rigid modified Zn(II)-Bis-cyclen based amphiphilic receptor for a template guided cooperative self-
assembly of nucleotides [Counter ions of the complexes to yield a neutral complex are not shown for clarity] 
The cholesterol bioconjugate of the Zn(II)-bis-cyclen complex was synthesized as shown in 
the Scheme 6. 
 
 
Scheme 6: Synthesis of a cholesterol bioconjugate of a Zn(II)-bis-cyclen complex   (a) Cholesterol acetylene, 
CuSO4, sodium ascorbate, TBTA, DMF, rt, 12h [yield: 87%]; (b) TFA, DCM, 4h,  basic ion exchanger resin 
[yield: quantitative]; (c) Zn(ClO4)2.6H2O,  MeOH / MeCN, reflux, o/n [yield: 99%]. Counter ions of the 
complexes to yield a neutral complex are not shown for clarity.  
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The amphiphilic Zn(II)-tetra-cyclen complex (Amp-1) and  was synthesized as shown in the 
Scheme 7. To combine two bis-cyclen moieties we considered using the bis-acetylene of carbazole. 
The hydrophobic C18 chain was incorporated into carbazole by nucleophilic substitution of the N-
heterocyle. The detailed experimental procedures and characterization are reported in the 
experimental and supporting data section. 
 
Scheme 7: Synthesis of amphiphilic modified Zn(II)-bis-cyclen based receptors  (a) 1-bromo-octadecane, 
K2CO3, DMF (dry) [yield: 95%]; (b) KI, KIO3, acetic acid, 85°C, 12h [yield: 80%]; (c) TMS acetylene, CuI, 
Pd(PPh3)2Cl2, NEt3, THF, rt, 8h [yield: 82%]; (d) K2CO3, MeOH [yield: quantitative] (e) CuI, NEt3, THF, rt, 8h 
[yield: 85%]; (f) TFA, DCM, 8h,  basic ion exchanger resin [yield: quantitative]; (g) Zn(ClO4)2.6H2O, 
2. Rigid Amphiphilic Molecular receptors, Bioconjugates and Radiopharmaceuticals based on Metal-
cyclen complexes via Click chemistry 
 
 
  54 
MeOH/MeCN, reflux, o/n [yield: 99%]. Counter ions of the complexes to yield a neutral complex are not shown 
for clarity. 
2.3.4.3 Concluding remarks 
We have synthesized new rigid Zn(II)-cyclen based amphiphilic receptors for a template 
guided cooperative self-assembly of nucleotides at interfaces. Investigations of the binding properties 
of new amphiphilic complex embedded surfaces are in progress. 
 
 
2.4 Experimental Section 
General methods and materials 
All reagent grade chemicals were used without purification unless otherwise specified. Cyanuric 
chloride, biotin, carbazole, propargyl amine, propargyl bromide were obtained from Aldrich and used 
as received.  
Acetylene of biotin[36]  and cholesterol[37] were synthesized following reported procedures. Mono and 
bis azide derivatives of cyanuric chloride were also synthesized adapting a reported procedure.[38]  
For gel phase studies, ovalbumin, phosphorylated bovine ɑ-casein and 70% dephosphorylated bovine 
ɑ-casein were obtained from Sigma Aldrcih. BSA was received from Roth. Streptavidin-Horseradish 
Proxidase (HRPO) was obtained from Biotrend Chemikalien Gmbh. 
 
NMR Spectra 
NMR spectra were measured with Bruker Avance 600 (1H: 600.1 MHz, 13C: 150.1 MHz, T = 300 
K), Bruker Avance 400 (1H: 400.1 MHz, 13C: 100.6 MHz, T = 300 K), Bruker Avance 300 (1H: 
300.1 MHz, 13C: 75.5 MHz, T = 300 K). The chemical shifts are reported in δ [ppm] relative to 
external standards (solvent residual peak). The spectra were analysed by first order, the coupling S-1 
constants are given in Hertz [Hz]. Characterisation of the signals: s = singlet, d = doublet, t = triplet, q 
= quartet, m = multiplet, br = broad, dd = double doublet. Integration is determined as the relative 
number of atoms. The solvent used is reported for each spectrum. 
 
Mass Spectra 
Mass spectra were obtained with Varian CH-5 (EI), Finnigan MAT 95 (CI; FAB and FD), Finnigan 
MAT TSQ 7000 (ESI). Xenon serves as the ionisation gas for FAB. 
 
IR Spectra 
IR spectra were recorded with a Bio-Rad FTS 2000 MX FT-IR and Bio-Rad FT-IR FTS 155. 
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SDS-PAGE 
Proteins were resolved on mini gels under denaturating and reducing Laemmli conditions on a 
PeqLab 45-1010-i apparatus. The gels consisted of a 5% acrylamide (w/v), 5mM Tris-HCl (pH 6.8), 
0.1% SDS (w/v) stacking gel and a 125 acrylamide (w/v), 375 mM Tris-HCl (pH 8.8), 0.1% SDS 
(w/v) running gel. A 25 mM Tris, 192 mM glycine, 0.1% SDS (w/v) running buffer (pH 8.3) was 
used. Protein samples were heated to 95 °C for 10 min with reducing and denaturating  RotiLoad 1 
sample buffer (purchased from Carl Roth, Germany) before being loaded onto the gel. The gels were 
run at 150V. Water cooling was used during the entire run.  
 
Staining 
The protein samples in the SDS gel phase was accomplished with 0.1% Coomassie R-250, 50% 
MeOH, 10% AcOH for 1h. Destaining was accomplished in 7% AcOH, 10% MeOH overnight.  
 
Western blot 
Unstained proteins were transferred from gel to nitrocellulose membrane with BioRad Mini Trans 
Blot Electrophoretic Transfer Cell apparatus. 25 mM Tris, 192 mM glycin, 01% SDS (w/v) buffer was 
used for blotting. Blots were run at 125 V for 1h.  
 
Chemiluminescent detection of proteins 
after blotting, nitrocellulose membranes were washed with BSA buffer (1% BSA (as blocking buffer), 
40 mM  Tris HCl, 300 mM NaCl, 1% (v/v) Tween 20 (pH 7.4) for 30 min. Membranes were then 
incubated in a solution of the biotinylated probe (10-6 M in BSA buffer) for 1 h. The membranes were 
then washed with BSA buffer for 3x 5 minutes and subsequently incubated with 0.2 μg/ ml of 
streptavidin-horseradish peroxidase (HRPO) for 30minutes. Unbound streptavidin-HRPO was washed 
away by treating with washing buffer for 3x 15 minutes. Detection was performed with ECL substrate 
(Thermo Scientific SuperSignal West Pico chemiluminescent substrate). The chemiluminescence 
detections of the membranes were done by Fujifilm LAS 3000 luminescent image analyzer. 
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Synthesis of Compound 4: In a round bottom flask, mono azide derivative of trichlorotriazine (2A) 
(0.2 g, 1.08 mmol) and K2CO3 (0.6 g, 4.32 mmol) were suspended in 70 ml of acetone. To this 
suspension a solution of threefold Boc-protected cyclen (3) (1.02 g, 2.16 mmol) in 30 ml acetone was 
slowly added. The reaction mixture was then heated under reflux for 12h. The solvent was removed 
under reduced pressure and the crude mixture was purified by column chromatography using 30% 
ethyl acetate in petrol ether as the eluent to get pure product 4 (yield: 20%). 
1H NMR (300MHz, CDCl3) δ [ppm]: 1.39 (s, 54H, CH3-BOC), 3.04-3.75 (br, m, 32H, CH2-cyclen; 
13C NMR (75MHz, CDCl3) δ [ppm]: 28.4, 31.7, 50.0, 53.8, 69.4, 79.9, 156.1, 168.2, 210.7; MS (ESI-
Q1MS) m/z (%) = 1063.8 (100) (MH+); M.P.: 87-89 °C; IR (ATR) [cm-1]: ~ = 2974, 2928, 2865, 
1694, 1540, 1361, 1169; MF: C48H84N14O12, FW: 1048.64 g/mol 
 
 
Synthesis of Compound 5: To a stirred solution of 4 (0.28 g, 0.29 mmol) in degassed dry DMF (3 
ml), acetylene of biotin (0.09 g, 0.35 mmol), CuSO4.5H2O (1 mg, 0.005 mmol, 0.02eq), sodium 
ascorbate (2 mg, 0.016 mmol 0.04 eq) and TBTA (4 mg, 0.02eq) were added and the reaction mixture 
was stirred at room temperature for 12 h. Then the solvent was evaporated. The residual solid was 
dissolved in DCM (50 mL) and successively washed by water (2 X 10 mL) and brine (10 mL). The 
organic layer was then dried on NaSO4 and evaporated under reduce pressure. The crude product was 
purified by column chromatography using 6:1 chloroform/methanol mixture to get 5 (yield: 90%). 
1H NMR (300MHz, CDCl3) δ [ppm]:1.33 (br, 2H), 1.40 (s, br, 54H) 1.62 (m, 4H), 2.18 (t, 2H), 2.70-
2.89 (m, 2H), 3.07-4.01(m, br, 33H), 4.29-4.38 (m, 2H), 4.47-4.59 (m, 2H), 6.72 (s, 1H), 7.32 (s, 1H), 
7.91 (br, 1H),  8.40 (s, 1H) ; 13C NMR (75MHz, CDCl3) δ [ppm]: 25.4, 27.9, 28.3, 28.4, 34.1, 35.8, 
40.6, 49.9, 50.3, 50.9, 55.7, 60.3, 61.6, 76.7, 80.1, 80.2, 121.1, 144.6, 156.3, 159.9, 164.8, 165.6, 
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173.2 ; MS (ES-MS) m/z (%) =1345.1(100) [MH+], 673.0 (65) [(M+2H)2+], 623.0 (65) [(M+2H)2+- 
Boc], 594.9 (30) [(M+2H)2+- Boc-C4H8]; MF: C62H105N17O14S, FW: 1344.67 g/mol 
 
 
Synthesis of Compound 6:  
Boc-deprotection of Compound 5: Compound 5 (0.25 g, 0.18 mmol) was dissolved in DCM. 
Trifluoroacetic acid (2 ml, 0.02 mol) was added to it and the reaction mixture was stirred for 4h. 
Subsequently DCM was evaporated and the obtained TFA salt was dissolved in water and passed 
through a basic ion exchanger column resin. The elution of the product was controlled by pH indicator 
paper (pH > 10) and was completed when pH again was neutral. The eluate was concentrated and 
lyophilised to yield the Boc-deprotected compound (yield: quantitative). 
1H NMR (300MHz, CDCl3) δ [ppm]:  1.42 (br, 2H), 1.67 (m, 4H), 2.26 (t, 2H), 2.68-2.72 (dd, 16H),  
2.81-3.00 (m, 10H), 3.09-3.17 (m,2H), 3.87 (m, br, 8H),  4.23-4.27 (m, 1H), 4.45-4.51 (m, 3H), 8.71 
(br, 1H),  8.63 (s, 1H) ; 13C NMR (75MHz, CDCl3) δ [ppm]: 26.8, 29.5, 29.7, 30.1, 35.5, 36.6, 41.1, 
47.1, 49.9, 50.1, 57.1, 61.6, 63.3, 123.2, 146.6, 161.1, 166.1, 167.9, 176.1; MS (ESI-MS) m/z (%) 
=744.46 (50) [MH+], 372.7 (50) [(M+2H)2+], 358.73(100) [(M+2H)2+- N2]; MF: C32H57N17O2S, FW: 
743.97 g/mol 
Metal complexation of Boc-deprotected compound 5: The Boc-deprotected compound (0.05g, 0.067 
mmol), was dissolved in 3 mL acetonitrile and ZnClO4.6H2O (0.05g, 0.13 mmol) dissolved in 
methanol was added slowly. The reaction mixture refluxed overnight under vigorously stirring. The 
hot reaction mixture was filtered and the filtrate was evaporated under reduced pressure to get the 
complex 6 (yield: 99%).  
1H NMR (300MHz, CDCl3) δ [ppm]:  1.39 (br, 2H), 1.61 (m, 4H), 2.21 (t, 2H), 2.51-2.70 (dd, 16H),  
2.75-3.00 (m, 10H), 3.09-3.15 (m,2H), 3.85 (m, br, 8H),  4.21-4.26 (m, 1H), 4.41-4.50 (m, 3H), 8.68 
(br, 1H),  8.61 (s, 1H) ; 13C NMR (75MHz, CDCl3) δ [ppm]: 22.1, 24.9, 27.8, 29.3, 34.8, 33.5, 42.7, 
44.7, 48.2, 51.2, 53.3, 130.3, 139.7, 167.3, 171.2; MS (ESI-MS) m/z (%) =744.46 (50) [MH+], 372.7 
(50) [(M+2H)2+], 358.73(100) [(M+2H)2+- N2]; MF: C32H57N17O2S, FW: 743.97 g/mol 
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Synthesis of Compound 8: Sodium hydrogen carbonate (1.34 g, 15.96 mmol) was added to a 
suspension of tetraazacyclododecane 7 (0.83 g, 4.83 mmol) in CH3CN (50 ml) and stirred for 15min. 
A solution of benzylbromoacetate (2.36 ml, 14.9 mmol) in CH3CN (10 ml) was added dropwise over 
30 min and the reaction mixture was refluxed for 12h. The reaction was monitored by TLC. After 12h 
the inorganic salt was filtered and filtrate was removed under reduced pressure. The crude residue was 
purified by column chromatography on silica gel (2% CH3OH in CH2Cl2) to get 8 as oily substance 
(yield: 45%). 
1H NMR (300MHz, CDCl3) δ [ppm]: 2.80-3.01 (br, m, 16H), 3.34 (s, 2H), 3.41 (s, 4H), 5.05 (s, 6H), 
7.27 (m, 15H) 9.89 (s, br, 1H); 13C NMR (75MHz, CDCl3) δ [ppm]:  47.3, 49.3, 51.4, 51.6, 57.1, 
66.5, 128.4, 128.5, 128.6, 135.3, 170.1, 171.1; MS (ESI-MS) m/z (%) = 615 (100) [M+]; MF: 
C35H44N4O6, FW: 616.75g/mol 
 
 
Synthesis of Compound 9: In a round bottom flask 2B (0.07 g, 0.33 mmol) and K2CO3 (0.18 g, 1.32 
mmol) were suspended in 10 ml of acetone. To this suspension 8 (0.19 g, 0.33 mmol) in 15 ml 
acetone were slowly added via a syringe. The reaction mixture was refluxed for 17h. The solvent was 
removed under reduced pressure. The crude product was purified by column chromatography on silica 
gel (30% ethyl acetate in petrol ether) to get pure compound 9 (yield: 30%). 
1H NMR (300MHz, CDCl3) δ [ppm]: 2.74-3.44 (br, m, 16H), 3.41 (s, 4H), 5.10 (s, 6H), 7.33 (m, 
15H); 13C NMR (75MHz, CDCl3) δ [ppm]:  47.3, 48.6, 49.3, 51.4, 51.6, 57.1, 66.5, 128.4, 128.5, 
128.6, 135.3, 170.1, 171.0 MS (ESI-MS) m/z (%) = 778.4 (100) [M+]; MF: C38H43N13O6, FW: 777.35 
g/mol   
2. Rigid Amphiphilic Molecular receptors, Bioconjugates and Radiopharmaceuticals based on Metal-
cyclen complexes via Click chemistry 
 
 
  59 
 
 
Synthesis of Compound 11: To a stirred solution of 4 (0.41 g, 0.39 mmol) in degassed dry DMF (3 
ml), acetylene of cholesterol (0.2g, 0.47 mmol), CuSO4.5H2O (1.5 mg, 0.007 mmol, 0.02eq), sodium 
ascorbate (3 mg, 0.016 mmol 0.04eq) and TBTA (5 mg, 0.02eq) were added and the reaction mixture 
was stirred at room temperature for 12 h. Then the solvent was evaporated. The residual solid was 
dissolved in DCM (50 mL) and successively washed by water (2 X 10 mL) and brine (10 mL). The 
organic layer was then dried on NaSO4 and evaporated under reduce pressure. The crude product was 
purified by column chromatography using 30% ethyl acetate in hexane to get 11 (yield: 87%).  
 
1H NMR (600MHz, CDCl3, COSY, HSQC, HMBC) δ [ppm]: 0.65 (s, 3H, 28), 0.82 (d, 3H, 25), 0.83 
(d, 3H, 24), 0.85-0.94 (m, 4H, 31+26), 0.93-1.01 (m, 5H, 15+20’+33), 1.01-1.03 (m, 1H, 9’), 1.03-
1.12 (m, 2H, 16’+18), 1.09-1.16 (m, 2H, 30’+22’), 1.24-1.28 (m, 1H, 17), 1.33-1.38 (m, 57H, Boc-
CH3+23+30+20), 1.40-1.41 (m, 3H, 8’+35), 1.42-1.52 (m, 4H, 13+21+21’+23), 1.52-1.54 (m, 1H, 
16), 1.75-1.89 (m, 2H, 9+17), 1.85-1.90 (m, 1H, 8), 1.88-2.01(m, 1H, 29), 2.31-2.35(m, 1H, 10), 3.09-
3.11 (m, 1H, 7), 3.18-4.01 (m, br, cyclen-CH2), 5.30-5.32 (m, 1H, 12); 13C NMR (150MHz, CDCl3, 
HSQC, HMBC) δ [ppm]: 10.9 (+, 1C, 28), 18.5 (+, 1C, 26), 19.1 (+, 1C, 33), 20.9 (-,1C, 21), 22.1 (+, 
1C, 24), 22.3 (+, 1C, 25), 23.8 (−, 1C, 30), 23.9 (−,1C, 16), 27.8 (+, 1C, 23), 28.1(−, 1C, 17), 28.2 (−, 
1C, 8), 28.4, 28.5 (+, Boc-CH3), 30.5 (−, 1C, 13), 31.5 (+, 1C, 14), 35.4 (+, 1C, 19), 35.9 (−, 1C, 20), 
36.2 (Cquat, 1C, 32), 36.9 (−, 1C, 9), 39.1 (−, 1C, 10), 39.2 (−, 1C, 22), 39.5 (−, 1C, 29), 42.1 (Cquat, 
1C, 27), 48.7, 48.9 (−, cyclen-CH2) 49.8 (+, 1C, 31), 55.9 (+, 1C, 18), 56.2 (+, 1C, 15), 67.2 (−, 1C, 
43), 80.1 (−, 1C, 7), 80.5, 80.7 (Cquat, C-Boc), 121.3 (+, 1C, 12), 140.8 (Cquat, 1C, 11), 153.2, 156.1 
(Cquart, C=O Boc), 168.2 (Cquart, triazine-CAryl-N); MS (ES-MS) m/z (%) =1505.6 (100) [MNH4+], 
1488.5 (70) [MH+], 761.8 (90) [(M+2NH4+)2+], 753.3 (20) [(MH++NH4+)2+; MF: C79H134N14O13, FW: 
1488.00g/mol. 
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Synthesis of Compound Amp-2: 
Boc-deprotection of Compound 11: Compound 11 (0.3 g, 0.21 mmol) was dissolved in DCM. 
Trifluoroacetic acid (3 ml, 0.03 mol) was added to it and the reaction mixture was stirred for 3h. 
Subsequently DCM was evaporated and the obtained TFA salt was dissolved in water and passed 
through a basic ion exchanger column resin. The elution of the product was controlled by pH indicator 
paper (pH > 10) and was completed when pH again was neutral. The eluate was concentrated and 
lyophilised to yield the Boc-deprotected compound (yield: quantitative). 
 
1H NMR (600MHz, CDCl3, COSY, HSQC, HMBC) δ [ppm]: 0.62 (s, 3H, 28), 0.80 (d, 3H, 25), 0.83 
(d, 3H, 24), 0.78-0.82 (m, 4H, 31+26), 0.91-0.95 (m, 5H, 15+20’+33), 1.01-1.03 (m, 1H, 9’), 1.03-
1.12 (m, 2H, 16’+18), 1.09-1.16 (m, 2H, 30’+22’), 1.21-1.23 (m, 1H, 17), 1.30-1.33 (m, 3H, 
23+30+20), 1.38-1.40 (m, 3H, 8’+35), 1.42-1.52 (m, 4H, 13+21+21’+23), 1.52-1.54 (m, 1H, 16), 
1.75-1.89 (m, 2H, 9+17), 1.85-1.90 (m, 1H, 8), 1.88-2.01(m, 1H, 29), 2.31-2.35(m, 1H, 10), 3.12-3.17 
(m, 1H, 7), 3.19-3.97 (m, br, cyclen-CH2), 5.29-5.30 (m, 1H, 12); 13C NMR (150MHz, CDCl3, 
HSQC, HMBC) δ [ppm]: 10.6 (+, 1C, 28), 18.1 (+, 1C, 26), 19.5 (+, 1C, 33), 20.9 (-,1C, 21), 22.1 (+, 
1C, 24), 22.3 (+, 1C, 25), 23.8 (−, 1C, 30), 23.9 (−,1C, 16), 27.8 (+, 1C, 23), 28.1(−, 1C, 17), 28.2 (−, 
1C, 8), 31.4 (−, 1C, 13), 31.5 (+, 1C, 14), 31.4 (+, 1C, 19), 35.9 (−, 1C, 20), 36.9 (−, 1C, 9), 39.1 (−, 
1C, 10), 39.2 (−, 1C, 22), 36.5 (−, 1C, 29), 42.1 (Cquat, 1C, 27), 48.2, 48.5 (−, cyclen-CH2) 49.8 (+, 
1C, 31), 57.1 (+, 1C, 18), 56.2 (+, 1C, 15), 67.2 (−, 1C, 43), 80.1 (−, 1C, 7), 80.5, 80.7 (Cquat, C-Boc), 
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121.3 (+, 1C, 12), 140.8 (Cquat, 1C, 11),165.7 (Cquart, triazine-CAryl-N); MS (ES-MS) m/z (%) =884 
(100) [MH+]; MF: C49H86N14O, FW: 887.30 g/mol. 
Metal complexation of Boc-deprotected compound 11: The Boc-deprotected compound (0.05g, 0.05 
mmol), was dissolved in 3 mL acetonitrile and ZnClO4.6H2O (0.05g, 0.13 mmol) dissolved in 
methanol was added slowly. The reaction mixture refluxed overnight under vigorously stirring. The 
hot reaction mixture was filtered and the filtrate was evaporated under reduced pressure to get amp-2 
(yield: 99%).  
1H NMR (600MHz, CDCl3, COSY, HSQC, HMBC) δ [ppm]: 0.60 (s, 3H, 28), 0.79 (d, 3H, 25), 0.81 
(d, 3H, 24), 0.83-0.91 (m, 4H, 31+26), 0.91-0.98 (m, 5H, 15+20’+33), 1.01-1.03 (m, 1H, 9’), 1.01-
1.09 (m, 2H, 16’+18), 1.05-1.11 (m, 2H, 30’+22’), 1.20-1.21 (m, 1H, 17), 1.33-1.38 (m, 3H, 
23+30+20), 1.38-1.40 (m, 3H, 8’+35), 1.42-1.47 (m, 4H, 13+21+21’+23), 1.51-1.54 (m, 1H, 16), 
1.75-1.89 (m, 2H, 9+17), 1.85-1.90 (m, 1H, 8), 1.88-2.01(m, 1H, 29), 2.31-2.35(m, 1H, 10), 3.09-3.11 
(m, 1H, 7), 3.18-4.01 (m, br, cyclen-CH2), 5.28-5.31 (m, 1H, 12); 13C NMR (150MHz, CDCl3, 
HSQC, HMBC) δ [ppm]: 9.9 (+, 1C, 28), 12.5 (+, 1C, 26), 14.1 (+, 1C, 33), 20.7 (-,1C, 21), 22.1 (+, 
1C, 24), 22.5 (+, 1C, 25), 23.7 (−, 1C, 30), 23.9 (−,1C, 16), 26.5 (+, 1C, 23), 28.0(−, 1C, 17), 27.9 (−, 
1C, 8), 28.4, 30.5 (−, 1C, 13), 31.5 (+, 1C, 14), 35.4 (+, 1C, 19), 35.9 (−, 1C, 20), 36.0 (Cquat, 1C, 32), 
36.9 (−, 1C, 9), 39.1 (−, 1C, 10), 39.2 (−, 1C, 22), 39.5 (−, 1C, 29), 40.1 (Cquat, 1C, 27), 47.7, 47.9 (−, 
cyclen-CH2) 49.6 (+, 1C, 31), 55.1 (+, 1C, 18), 56.2 (+, 1C, 15), 67.2 (−, 1C, 43), 80.1 (−, 1C, 7), 80.5 
(Cquat, C-Boc), 118.3 (+, 1C, 12), 142.8 (Cquat, 1C, 11), 161.3 (Cquart, triazine-CAryl-N); MS (ES-MS) 
m/z (%) =1016.6 (100) [MH+]; MF: C49H86N14OZn2, FW: 1018.06g/mol. 
 
 
Synthesis of Compound 12A: The mixture of carbazole 12 (1.5 g, 8.97 mmol), 1-bromo-octadecane 
(1.8 g, 5.39 mmol) and potassium carbonate (2 g, 14.4 mmol) in anhydrous DMF (7 ml) was heated at 
50° C for 24 h under nitrogen and then 50 ml water was added. DCM was used in three portions (20 
ml each) to extract the product. The organic layer was washed with water and dried over MgSO4. The 
solvent was removed under reduced pressure to get the crude product which was subsequently 
purified by column chromatography using hexane as eluent (yield: 95%) 
1H NMR (300MHz, CDCl3) δ [ppm]:  8.11 (d, 3J= 7.7 Hz, 2H), 7.48-7.39 (m, 4H), 7.22 (t, 3J = 7.4 
Hz, 2H), 4.30 (t, 3J =7.2 Hz, 2H), 1.89-1.85 (m, 2H), 1.40-1.23 (m, 30H), 0.88 (t, 3J = 6.9 Hz, 3H); 
13C NMR (75MHz, CDCl3) δ [ppm]: 140.5, 125.7, 122.9, 120.4, 118.8, 108.8, 43.2, 32.1, 29.9, 29.83, 
29.80, 29.76, 29.73, 29.66, 29.60, 29.57, 29.5, 29.1, 27.5, 22.9, 14.3; MS (ESI-MS) m/z (%) = 418.9 
(100) [M+]; MF: C30H45N, FW: 419.69 g/mol   
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Synthesis of Compound 13: In a round bottom flask equipped with a condenser, 9-
octadecylcarbazole 12A (5.2 g, 12.4 mmol), potassium iodide (2.6 g, 16.3 mmol) and potassium 
iodate (3.5 g (28.1 mmol) were dissolved in 100 mL acetic acid under gentle stirring. The mixture was 
heated at 80 °C for 12 h. After the reaction mixture was cooled to room temperature, the crude 
iodinated product was obtained by filtration. The filter cake was washed consecutively with 100 mL 
of water, sodium bicarbonate (1 M), sodium thiosulfate solution (1 M), and water. Compound 13 was 
obtained a white solid after recrystallization from the ethanol/water mixture (2:1 by volume) (yield: 
80%). 
1H NMR (300MHz, CDCl3) δ [ppm]:  8.33 (s, 2H), 7.72 (d, 3J= 8.6 Hz, 2H), 7.18 (d, 3J = 8.6 Hz, 
2H), 4.22 (t, 3J= 7.1 Hz, 2H), 1.81-1.79 (m, 2H), 1.29-1.22 (m, 30H), 0.88 (t, 3J = 7.0 Hz, 3H); 13C 
NMR (75MHz, CDCl3) δ [ppm]: 139.3, 129.0, 123.4, 111.9, 110.4, 43.3, 31.95, 29.7, 29.6, 29.6, 29.5, 
29.5, 29.4, 29.3, 29.3, 28.8, 27.2, 22.7, 14.1 MS (ESI-MS) m/z (%) = 670.4 (100) [M+]; MF: 
C30H43I2N, FW: 671.48 g/mol. 
 
Synthesis of Compound 14: To a flask containing Pd(PPh3)2Cl2 (0.15 g, 0.21 mmol), CuI (0.06 g, 
0.33 mmol), and 13 (6.08 g, 9.0 mmol) were added (trimethylsilyl) acetylene (2.65 g, 38.4 mmol) in 
triethylamine (75 mL) and tetrahydrofuran (125 mL). The mixture was stirred at room temperature 
under nitrogen atmosphere for 48 h and then filtered. The filtrate was concentrated and the crude solid 
was purified by column chromatography on silica gel using petroleum ether as an eluent to get 3, 6-
Bis[(trimethylsilyl)ethynyl]-9-octadecylcarbazole, 14 (yield: 82%).  
1H NMR (300MHz, CDCl3) δ [ppm]: 8.20 (s, 2H), 7.59 (d, 3J =8.2 Hz, 2H), 7.30 (d, 3J = 8.5 Hz, 2H), 
4.22 (t, 3J = 7.2 Hz, 2H), 1.84-1.75 (m, 2H), 1.41-1.27 (m, 29H), 0.87 (t, 3J = 7.3 Hz, 3H), 0.31 (s, 
18H); 13C NMR (75MHz, CDCl3) δ [ppm]: 139.4, 129.0, 123.7, 121.2, 112.9, 107.7, 106.5, 88.3, 
42.2, 30.9, 28.6, 28.6, 28.5, 28.5, 28.3, 27.8, 26.1, 21.6, 13.1;  MS (EI-MS) m/z (%) = 611.3(100%) 
[M+]; MF: C40H61NSi2, FW: 612.09 g/mol   
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Synthesis of Compound 15: K2CO3 aqueous solution (1.9 M, 4 ml) was added to a stirred solution of 
3, 6-bis [(trimethylsilyl)ethynyl]-9-octadecylcarbazole 14 (1.55 g, 2.5 mmol) in methanol (148 ml). 
The mixture was stirred at room temperature under nitrogen atmosphere for 1h and then diluted with 
diethyl ether and water. The aqueous phase was washed with diethyl ether, and the combined organic 
phase was washed with saturated brine. The organic phase was dried over MgSO4, and the solvent 
was evaporated under reduced pressure. The crude residual material was purified by column 
chromatography on silica gel using petroleum ether as an eluent to give 15 as a light yellow solid 
(yield: quantitative). 
1H NMR (300MHz, CDCl3) δ [ppm]: 0.88 (t, 3J = 7.3 Hz, 3H), 1.32-1.25 (m, 32H), 1.84-1.80 (m, 
2H), 3.08 (s, 2H), 4.27 (t, 3J =7.2 Hz, 2H), 7.35 (d, 3J= 8.5 Hz, 2H), 7.61 (d, 3J= 8.5 Hz, 2H), 8.22 (s, 
2H); 13C NMR (75MHz, CDCl3) δ [ppm]: 140.67, 130.13, 124.78, 122.26, 112.69, 108.96, 84.75, 
43.34, 31.95, 29.72, 29.68, 29.64, 29.60, 29.54, 29.47, 29.38, 28.91, 27.23, 22.71, 14.14; MS (EI-MS) 
m/z (%) = 468.4 (100) [MH+]; MF: C34H45N, FW: 467.36 g/mol .  
 
Synthesis of Compound 16: To a stirred solution of 15 (0.5 g, 1.06 mmol) in degassed dry THF (10 
mL), biscyclene mono azide 2A (0.567 g, 0.053 mmol), CuI (0.005 g, 6 mol %) and triethylamine (1 
ml, 9.8 mmol) were added and the reaction mixture was stirred at room temperature for 12 h. The 
product was extracted from the reaction mixture with diethylether (3x10 mL). Then combined organic 
extract was evaporated under reduced pressure and the crude product was purified by column 
chromatography using 5% ethyl acetate in petroleum ether as eluent (yield: 85%) 
1H NMR (300MHz, CDCl3) δ [ppm]:  0.79 (t, 3J = 7.3 Hz, 3H), 1.16-1.20 (m, 32H), 1.40-1.34 (br, s, 
108H), 1.96-1.94 (m, 2H), 3.36-3.77(m, br, 66H), 7.36 (d, 3J= 9Hz, 2H), 8.01 (d, 3J=9Hz, 2H), 8.72 (s, 
2H); 13C NMR (75MHz, CDCl3) δ [ppm]: 14.1, 21.0, 22.6, 27.3, 28.5, 29.0, 29.3, 29.4, 29.6, 31.9, 
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50.9, 56.2, 60.3, 80.2, 109.0, 118.4, 121.5, 123.2, 124.5, 140.8, 148.2, 156.5, 160.13; MS (EI-MS) 
m/z (%) =  1298.0 (100) [(M+2H) 2+], 1306.5 (45) [(MH++ MH4+) 2+]; MF: C132H217N29O24, FW: 
2594.32g/mol .  
 
Synthesis of Compound Amp-1: 
Boc-deprotection of Compound 16: Compound 16 (0.5 g, 0.19 mmol) was dissolved in DCM. 
Trifluoroacetic acid (2 ml, 0.02 mol) was added to it and the reaction mixture was stirred for 4h. 
Subsequently DCM was evaporated and the obtained TFA salt was dissolved in water and passed 
through a basic ion exchanger column resin. The elution of the product was controlled by pH indicator 
paper (pH > 10) and was completed when pH again was neutral. The eluate was concentrated and 
lyophilised to yield the Boc-deprotected compound (yield: quantitative). 
1H NMR (300MHz, CDCl3) δ [ppm]:  0.75 (t, 3J = 7.3 Hz, 3H), 1.18-1.23 (m, 32H), 1.98-2.01 (m, 
2H), 3.31-3.58(m, br, 66H), 7.32 (d, 3J= 9Hz, 2H), 7.97 (d, 3J=9Hz, 2H), 8.71 (s, 2H); 13C NMR 
(75MHz, CDCl3) δ [ppm]: 14.1, 22.6, 27.3, 29.2, 29.5, 29.6, 32.1, 58.2, 60.3, 80.5, 111.0, 119.4, 
121.9, 123.2,  140.8, 148.3; MS (ESI-MS) m/z (%) =1391(100) [MH+]; MF: C72H121N29, FW: 
1392.93 g/mol 
Metal complexation of Boc-deprotected compound 16: The Boc-deprotected compound (0.05g, 0.035 
mmol), was dissolved in 3 mL acetonitrile and ZnClO4.6H2O (0.06g, 0.14 mmol) dissolved in 
methanol was added slowly. The reaction mixture refluxed overnight under vigorously stirring. The 
hot reaction mixture was filtered and the filtrate was evaporated under reduced pressure to get the 
complex 6 (yield: 99%).  
1H NMR (300MHz, CDCl3) δ [ppm]: 0.72 (t, 3J = 7.3 Hz, 3H), 1.19-1.24 (m, 32H), 1.97-2.01 (m, 
2H), 3.29-3.50(m, br, 66H), 7.35(d, 3J= 9Hz, 2H), 7.93 (d, 3J=9Hz, 2H), 8.67 (s, 2H); 13C NMR 
(75MHz, CDCl3) δ [ppm]: 14.2, 22.7, 27.3, 29.3, 29.7, 31.9, 50.1, 60.3, 80.1, 80.2, 111.0, 119.4, 
120.9, 123.3,  141.0, 148.2; MS (ESI-MS) m/z (%) =1653.4 (80) [MH+]; MF: C72H121N29Zn4, FW: 
1654.45g/mol 
 
 
2. Rigid Amphiphilic Molecular receptors, Bioconjugates and Radiopharmaceuticals based on Metal-
cyclen complexes via Click chemistry 
 
 
  65 
2.5 Supporting Data 
1H and 13C spectra of synthesized compounds 
 
 
1H-NMR spectrum of compound 4 (300 MHz, CDCl3) 
 
 
 
13C-NMR spectrum of compound 4 (75 MHz, CDCl3) 
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1H-NMR spectrum of compound 16 (300 MHz, CDCl3) 
 
 
 
1H-NMR spectrum of compound 5 (300 MHz, CDC3) 
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13C-NMR spectrum of compound 5 (75 MHz, CDCl3) 
 
 
13C (DEPT 135)-NMR spectrum of compound 5 (150 MHz, CDCl3) 
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13C (DEPT 90)-NMR spectrum of compound 5 (150 MHz, CDCl3) 
 
 
1H-NMR spectrum of Boc-deprotected compound 5 (300 MHz, CDCl3) 
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13C-NMR spectrum of Boc-deprotected compound 5 (75 MHz, CDCl3) 
 
 
13C (DEPT 135)-NMR spectrum of Boc-deprotected compound 5 (150 MHz, CDCl3) 
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1H-NMR spectrum of compound 11 (300 MHz, CDC3) 
 
 
13C-NMR spectrum of compound 11 (75 MHz, CDCl3) 
 
2. Rigid Amphiphilic Molecular receptors, Bioconjugates and Radiopharmaceuticals based on Metal-
cyclen complexes via Click chemistry 
 
 
  71 
 
1H-NMR spectrum of Boc-deprotected compound 11 (300 MHz, CDC3) 
 
 
13C-NMR spectrum of Boc-deprotected compound 11 (75 MHz, CDCl3) 
 
 
2. Rigid Amphiphilic Molecular receptors, Bioconjugates and Radiopharmaceuticals based on Metal-
cyclen complexes via Click chemistry 
 
 
  72 
2.6 References 
[1] H. C. Kolb, K. B. Sharpless Drug Discov. Today 2003, 8, 1128. 
[2] C. O. Kappe, E. Van der Eycken Chem. Soc. Rev. 2010, 39, 1280. 
[3] H. C. Kolb, M. G. Finn, K. B. Sharpless Angew. Chem. Int. Ed. 2001, 40, 2004. 
[4] R. Huisgen J. Org. Chem. 1976, 41, 403. 
[5] J. E. Moses, A. D. Moorhouse Chem. Soc. Rev. 2007, 36, 1249. 
[6] C. W. Tornøe, C. Christensen, M. Meldal J. Org. Chem. 2002, 67, 3057. 
[7] V. V. Rostovtsev, L. G. Green, V. V. Fokin, K. B. Sharpless Angew. Chem. Int. Ed. 2002, 41, 
2596. 
[8] M. Meldal, C. W. Tornøe Chem. Rev. 2008, 108, 2952. 
[9] G. T. Hermanson Bioconjugate Techniques, Vol. I, 1996. 
[10] R. Langer, D. A. Tirrell Nature 2004, 428 487. 
[11] S. S. van Berkel, M. B. van Eldijk, J. C. M. van Hest Angew. Chem. Int. Ed. 2011, 50, 8806. 
[12] E. M. Sletten, C. R. Bertozzi Acc. Chem. Res. 2011, 44, 666. 
[13] a)J.-F. Lutz, H. G. Börner Prog. Polym. Sci. 2008, 33, 1; b)L. Yi, J. Shi, S. Gao, S. Li, C. Niu, 
Z. Xi Tetrahedron Lett. 2009, 50, 759; c)Q. Wang, T. R. Chan, R. Hilgraf, V. V. Fokin, K. B. 
Sharpless, M. G. Finn J. Am. Chem. Soc. 2003, 125, 3192; d)K. Nwe, M. W. Brechbiel 
Cancer Biother Radiopharm. 2009, 24, 289. 
[14] J. W. Chin, S. W. Santoro, A. B. Martin, D. S. King, L. Wang, P. G. Schultz J. Am. Chem. 
Soc. 2002, 124, 9026. 
[15] C. W. Tornøe, C. Christensen, M. Meldal J. Org. Chem. 2002, 67, 3057. 
[16] A. J. Link, D. A. Tirrell J. Am. Chem. Soc. 2003, 125, 11164. 
[17] L. J. Cruz, C. Cuevas, L. M. Cañedo, E. Giralt, F. Albericio J. Org. Chem. 2005, 71, 3339. 
[18] J. Gierlich, G. A. Burley, P. M. E. Gramlich, D. M. Hammond, T. Carell J. Org. Lett. 2006, 8, 
3639. 
[19] J. C. Walsh, H. C. Kolb CHIMIA Int. J. Chem. 2010, 64, 29. 
[20] S. Maschauer, J. Einsiedel, R. Haubner, C. Hocke, M. Ocker, H. Hübner, T. Kuwert, P. 
Gmeiner, O. Prante Angew. Chem. Int. Ed. 2010, 49, 976. 
[21] a)L. S. Campbell-Verduyn, L. Mirfeizi, A. K. Schoonen, R. A. Dierckx, P. H. Elsinga, B. L. 
Feringa Angew. Chem. Int. Ed. 2011, 50, 11117; b)T. L. Ross, M. Honer, P. Y. H. Lam, T. L. 
Mindt, V. Groehn, R. Schibli, P. A. Schubiger, S. M. Ametamey Bioconjugate Chem. 2008, 
19, 2462. 
[22] a)C. M. Kam, A. S. Abuelyaman, Z. Li, D. Hudig, J. C. Powers Bioconjugate Chem. 1993, 4, 
560; b)A. S. Abuelyaman, D. Hudig, S. L. Woodard, J. C. Powers Bioconjugate Chem. 1994, 
5, 400. 
2. Rigid Amphiphilic Molecular receptors, Bioconjugates and Radiopharmaceuticals based on Metal-
cyclen complexes via Click chemistry 
 
 
  73 
[23] A. B. Berger, P. M. Vitorino, M. Bogyo Am J Pharmacogenomics 2004, 4, 371. 
[24] W. Zhang, H. T. Liu Cell Res 2002, 12, 9. 
[25] E.J. McManus, K. Sakamoto, L.J. Armit, L. Ronaldson, N.  Shpiro EMBO J. 2005, 24, 1571. 
[26] R. Hayes Semin Nucl Med. 1978, 8. 
[27] a)C. J. Anderson, M. J. Welch Chem. Rev. 1999, 99, 2219; b)S. Vallabhajosula, in Molecular 
Imaging, Springer Berlin Heidelberg, 2009, pp. 179. 
[28] P. McQuade, D. W. McCarthy, M. J. Welch, in Positron Emission Tomography: Basic 
Science and Clinical Practice (Eds.: D. L. Bailey, D. W. Townsend, P. E. Valk, M. N. 
Maisey), Springer London, 2005, pp. 237. 
[29] C. Burchardt, P. J. Riss, F. Zoller, S. Maschauer, O. Prante, T. Kuwert, F. Roesch Bioorg. 
Med. Chem. Lett. 2009, 19, 3498. 
[30] J. D. Badjić, A. Nelson, S. J. Cantrill, W. B. Turnbull, J. F. Stoddart Acc. Chem. Res. 2005, 
38, 723. 
[31] L. J. Prins, D. N. Reinhoudt, P. Timmerman Angew. Chem. Int. Ed. 2001, 40, 2382. 
[32] M. Weisser, J. Käshammer, B. Menges, J. Matsumoto, F. Nakamura, K. Ijiro, M. Shimomura, 
S. Mittler J. Am. Chem. Soc. 1999, 122, 87. 
[33] K. Kurihara, K. Ohto, Y. Honda, T. Kunitake J. Am. Chem. Soc. 1991, 113, 5077. 
[34] a)D. S. Turygin, M. Subat, O. A. Raitman, V. V. Arslanov, B. König, M. A. Kalinina Angew. 
Chem. Int. Ed. 2006, 45, 5340; b)J. C. Love, L. A. Estroff, J. K. Kriebel, R. G. Nuzzo, G. M. 
Whitesides Chem. Rev. 2005, 105, 1103; c)D. A. Offord, C. M. John, J. H. Griffin Langmuir 
1994, 10, 761; d)W. A. Hayes, H. Kim, X. Yue, S. S. Perry, C. Shannon Langmuir 1997, 13, 
2511. 
[35] a)M. Sugahara, M. Uragami, X. Yan, S. L. Regen J. Am. Chem. Soc. 2001, 123, 7939; b)D. 
Needham, R. S. Nunn Biophys. J. 1990, 58, 997; c)F. A. Nezil, M. Bloom Biophys. J. 1992, 
61, 1176; d)M. Doxastakis, A. K. Sum, J. J. de Pablo J. Phys. Chem. B 2005, 109, 24173; 
e)R. K. Pandey, K. A. Suresh, V. Lakshminarayanan J. Colloid Interface Sci. 2007, 315, 528; 
f)K. Tu, M. L. Klein, D. J. Tobias Biophys. J. 1998, 75, 2147. 
[36] B. He, S. Velaparthi, G. Pieffet, C. Pennington, A. Mahesh, D. L. Holzle, M. Brunsteiner, R. 
van Breemen, S. Y. Blond, P. A. Petukhov J. Med. Chem. 2009, 52, 7003. 
[37] G. Godeau, C. Staedel, P. Barthélémy J. Med. Chem. 2008, 51, 4374. 
[38] G. V. Malkov, A. V. Shastin, Y. I. Estrin, E. R. Badamshina, Y. M. Mikhailov Propellants 
Explos. Pyrotech. 2008, 33, 431. 
 
 
 
2. Rigid Amphiphilic Molecular receptors, Bioconjugates and Radiopharmaceuticals based on Metal-
cyclen complexes via Click chemistry 
 
 
  74 
 
 
 
 
3. Phosphorescent Small Unilamellar Vesicles with embedded Amphiphilic Lanthanide complexes 
 
 
   75 
 
 
 
Chapter 3 
Phosphorescent Small Unilamellar Vesicles with 
embedded Amphiphilic Lanthanide complexes 
 
 
 
 
 
 
 
 
 
 
 
 
“Lanthanons – these elements perplex us in our researches, baffle us in our speculations, and 
haunt us in our very dreams. They stretch like an unknown sea before us; mocking, 
mystifying and murmuring strange revelations and possibilities.” 
 
Sir William Crookes, in an address to the Royal Society, February 1887 
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3.1 General Introduction 
3.1.1 Lanthanides: Relevance  
Lanthanides occupy unique positions in the periodic table, which correspond to the first 
period of f-block elements from lanthanum to lutetium, and the electronic configuration [Xe] 4fn 5s2 
5p6 where n varies from 0 to 14.They are the subset of rare earth elements with rich photophysical and 
coordination chemistry. 
The characteristic oxidation state of the lanthanide elements is +3. In addition to that, in 
reducing conditions, europium, samarium and ytterbium can be stable in +2 oxidation states; also, 
Ce3+ can lose its single f electron to form Ce4+ with the stable electronic configuration of xenon.[1] 
The trivalent lanthanides are hard acids and form stable ionic complexes with oxygen donor 
ligands rather than nitrogen donor ligands. The ionic character of bonding also leads to rapid ligand 
exchange in solution.[2] The coordination number of [Ln(H2O)n]3+ where the anion is a poor ligand 
tends to be 9 for the early lanthanides (La-Eu) as shown by many X-ray studies. The nine water 
molecules in [Ln(H2O)9]3+ are typically found in a tricapped trigonal prismatic arrangement. The 
degree of hydration decreases in progression along the series.[1]  
The 4f electrons of lanthanides are well shielded from the environment, consequently the 
spectroscopic and magnetic properties of lanthanides are unaffected by the environment. The 
absorption spectra of lanthanide cations result from f-f transitions and are sharp and line like as 
opposed to the broad absorptions of transition metals, as broadening effect of ligand vibrations is 
minimized because of deeply buried 4f orbitals.  
 
3.1.2 Sensitized Lanthanide Luminescence: Principles and Advantages 
All tripositive lanthanide ions, except La(III) and Lu(III)are luminescent. The f–f emission 
lines of Ln(III) cover the entire spectrum ranging from UV (Gd(III)) to visible (e.g., Pr(III), Sm(III), 
Eu(III), Tb(III), Dy(III), Tm(III)) and near-infrared (NIR, e.g., Pr(III), Nd(III), Ho(III), Er(III), 
Yb(III)). An important parameter characterizing the emission of light from a Ln(III) ion is the lifetime 
of the excited state, ߬௢௕௦. Since the dipole strengths of f–f transitions are very small, lanthanide ions 
have very low molar absorptivities and can only be effectively excited by lasers; lanthanide 
luminescence can be significantly enhanced by chelating ligands in a process called ‘sensitization’. In 
sensitized lanthanide luminescence, the chromophore is normally an aromatic or unsaturated organic 
molecule that is either anionic or has a strong dipole moment to coordinate to the Ln(III) ion. 
However intermolecular sensitisation of lanthanide ions are also reported in gel matrix and also in 
micellar medium, which involves non covalent co-embedding of lanthanide ion and the sensitizing 
chromophore.[3]  
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Figure 1: Energy level diagram, also known as a Dieke diagram, depicting the free ion energy levels of the 
trivalent lanthanide ions from Ce3+ (4f1) to Yb3+ (4f13). [Reprinted with permission from the quoted reference][4] 
 
The sensitized luminescence of lanthanide complexes offers several advantages over the 
classical organic dyes for the use in complex biological medium.[5] 
1. The lanthanide emissions are Laporte forbidden and are therefore characterized by extremely 
long luminescence lifetimes. The emission life times of europium and terbium are in the 
millisecond range and that of samarium and dysprosium are in the microsecond range. Their 
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long lived excited states allow the short-lived background fluorescence to disperse before the 
lanthanide emission occurs. 
2. The sensitised emission of a lanthanide complex gives rise to large Stokes shift between the 
absorption of the antenna and the emission of the lanthanide, hence avoiding the 
concentration dependent self absorption problems. 
 
 
(a)                                                                              (b) 
Figure 2: Unique fluorescence properties of lanthanides (a) long luminescence decay times [adapted from the 
quoted reference][6] (b) large Stokes’ shift 
3. The lanthanides have very narrow band emission spectra and these are insensitive to the 
environmental changes. The line like emission bands can also give a rise to better signal to 
noise ratio compared to fluorescent bands (several hundred nm). 
4. The long wavelengths at which the lanthanides emit (480-620nm for Tb (III)) occur beyond 
the absorbance of body tissue, which is important for signal quality. Furthermore, ions such as 
Yb(III) and Nd(III) emit at even longer wavelengths in the near infrared part of the spectrum, 
which is particularly attractive for diagnostic applications.[7] 
5. The lanthanide emission spectra do not completely overlap with one another, hence multiple 
lanthanide probes can be employed for concurrent monitor of several analytes.    
 
3.1.3 Phospholipid based Liposomes: Introduction 
 First described by the British haematologist Dr. Alec D Bangham in 1961[8] at the Babraham 
Institute, Cambridge, liposomes are nano size artificial vesicles of spherical shape that can be 
produced from natural phospholipids and cholesterol. Since their discovery, they are versatile tool in 
many scientific disciplines like chemistry, biology, biochemistry, physics and medicine and have 
become paradigms for biomembranes, instructive models of selfassembling colloids, and vehicles for 
pharmaceutical, diagnostic, and cosmetic agents.  
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Liposomes are composed of natural phospholipids and may also contain mixed lipid chains with 
surfactant properties (e.g. phosphatidylethanolamine). Liposomes can be classified according to their 
lamellarity (uni-, oligo-, and multi-lamellar vesicles), size (small, intermediate, or large) and 
preparation method (such as reverse phase evaporation vesicles, VETs). Unilamellar vesicles are 
spherical concentric unilamellar (one layer) structures and generally have diameters of 50–250 nm.  
Multilamellar vesicles comprise several spherically concentric lipid bilayers and have diameters of 1–
5 μm.[9] These spherical nanoparticles (NPs) with unilamellar or multilamellar structures separate and 
encapsulate an aqueous interior from bulk aqueous solvent. The lamellae of liposomes are composed 
of a bilayer of either lipid with a hydrophobic midplane to separate the two aqueous volumes. 
Distearoylphosphatidylcholine is an example of a lipid material commonly used for assembling 
liposomes. [10]   
The properties of liposomes make them useful for different applications. They show structural 
stability on dilution, varying permeability of the bilayer to different molecules, ability to entrap both 
water soluble and insoluble substances and deliver them into desired environments. 
The size, lamellarity (unilamellar or multilamellar) and lipid composition of the bilayers 
influence many of the properties like the fluidity, permeability, stability and structure -these can be 
controlled and customized to serve specific needs. The properties are also influenced by external 
parameters like the temperature, ionic strength and the presence of certain molecules nearby.[11]  
 
 
Figure 3: A representative diagram of the steric organization of a liposome (left) and a micelle (middle); 
Liposomes are constructed by lipid bilayer (right). [Reprinted with permission from the quoted reference][12]  
3.1.4 Liposomal stability and surface modification chemistry 
For the last five decades, the interest in the liposomes or amphiphilic nanoparticles arises 
from the combination of nanoscale size with the nearly infinite diversity of physical properties and 
chemical functionality that can be obtained through organic chemistry.[10] 
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Liposomal stability: stealth liposomes 
Liposomes have been investigated for many years in the biomedical field and their application 
in in vivo drug delivery, [13] in gene therapy [14] and as model systems for studying biological 
membranes [15] are longstanding goals for many research projects. The main advantages of using 
liposomes include: i) the high biocompatibility, ii) the easiness of preparation, iii) the chemical 
versatility that allows the loading of hydrophilic, amphiphilic, and lipophilic compounds, iv) the 
simple modulation of their pharmacokinetic properties by changing the chemical composition of the 
bilayer components.[16] For in vivo drug delivery and gene therapy, one of the most critical aspects is 
to improve liposome stability and enhance their circulation times in the blood. Conventional 
liposomes injected in blood stream are found to be unstable. The physicochemical properties of 
liposomes, such as net surface charge, hydrophobicity, size, fluidity, and packing of the lipid bilayers, 
influence their stability and the type of proteins that bind to them.[17] To overcome these problems 
there had been many attempts towards surface modification of liposomes by manipulating the lipid 
contents. For example, including ganglioside GM1 into liposomes leads to significantly enhanced 
stability in serum. Another major improvement in increasing liposome stability was achieved by 
introducing polyethylene glycol (PEG) as polymeric stabilizer (Stealth liposomes).  
PEG can be incorporated on the liposomal surface in different ways, but the most widely used 
method is by attaching polyethylene glycol (PEG) chains covalently to the polar head groups of 
phospholipids. Surface modification of liposomes with PEG has demonstrated several biological and 
technological advantages. One major advantage of using stealth liposomes in biology is its longer 
blood circulation time (hours) compared to conventional liposomes (minutes).[18] PEG, which is a 
strongly hygroscopic synthetic polymer, strongly influences the physicochemical properties of the 
lipid bilayer. Some remarkable effects are  
(a) Upon incorporation in the phospholipid bilayer, PEG changes the thermotropic phase 
behaviour of the lipids. There are reports of increase in pre-transition (Tp) and transition 
(Tm) temperature of lipids in small unilamellar vesicles and multilamellar vesicles 
(MLV) with increase in concentration of the incorporated PEG.[19] Based on DSC and 
ESR measurements, these changes were proposed to be due to the decrease in water 
content incorporated between phospholipid bilayer upon addition of poly-(ethylene 
glycol).[20] 
(b) There are some reports of loss of pre-transition temperature of phospholipids upon 
incorporation of PEG into lipid bilayer.[21] 
(c) Poly-(ethylene glycol) reduces the degree of the segmental lipid chain motion in the 
hydrocarbon region of some phospholipid layers in the gel phase. The motional restriction 
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of the labels due to PEG is reported to be more pronounced in ULVs than in MLVs of 
some phospholipids. These observations was explained in terms of the packing density of 
the hydrocarbon region of the phospholipid bilayers which increases with increase in 
concentration of  incorporated high molecular weight PEG.[21] 
z 
Figure 4: [Top] Schematic diagrams of poly-(ethylene glycol) (PEG) configurations regimes (mushroom, brush 
and pancake) for polymer grafted to the surface of liposome bilayer [Reprinted with permission from the quoted 
reference][9] [Bottom] Chemical structures of distearoylphophatidylcholine (DSPC), 
distearoylphophatidylethanolamine after conjugation with poly-(ethylene glycol) (PEG) (DSPE-PEG) 
 
Liposomal surface modification  
 
The introduction of functionalized amphiphiles into a liposomal surface has proven to be an 
effective strategy for developing liposomal conjugates via. Functional groups were introduced at the 
stage of liposome formation employing various lipids including the recognizable (e.g. biotin-labeled) 
ones by well established methods.[22]  
To prepare modified liposomes with controlled properties, proteins, peptides, polymers and other 
molecules are chemically conjugated to liposomes using standard crosslinking chemistry.[23] The 
conjugation methodologies usually are based on three reactions: amide bond formation via activated 
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carboxyl groups and amines, thioether bond formation by reaction between maleimide derivatives and 
thiols, and disulphide bond formation via reaction between pyridyldithiols and thiols. Some other 
approaches involve the formation of carbamate bonds.[24] Many of the activated lipids used in these 
processes are commercially available.[25] 
 
 
 
Figure 5: Some of the frequently used head group modified functionalized lipids 
 
Functionalized vesicles or  liposomes designed and prepared from different synthetic 
amphiphiles have been reported in the development of novel catalytic systems [26] or nanoscale 
systems or biosensors for molecular recognitions.[22, 27] Molecular recognition and sensing at 
interfaces are reported to be more effective relative to isotropic media, since the interacting groups are 
located at the organized liposomal surface. In fact, the binding constants between complementary 
moieties differ by some orders of magnitude for various types of molecular aggregates.[28] Also, even 
less-catalytically active small molecules can be self-assembled to form bilayer vesicles and, in doing 
so, gain unique catalytic properties for a given molecular transformation.[29] Incorporation of the 
recognition unit into the lipid bilayer [30] by synthetic modification of lipids is one possible approach. 
Co-embedding of an amphiphilic recognition unit into lipids to form liposomes is an alternative.[3a, 31] 
There are recent reports of incorporation of amphiphilic metal complexes in the liposome for effective 
molecular recognition and efficient catalysis.[31]  
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Figure 6: Amphiphilic metal complexes embedded in liposomes for molecular recognition and catalysis [31b, 32] 
 
3.1.5 Lanthanide complexes and liposomes 
Due to their rich photophysical properties, lanthanide complexes are in commercially applied 
as highly sensitive and selective probes in heterogeneous and homogeneous immunoassays, and in 
DNA assays.  
Liposomes have been exploited to generate highly sensitive CEST (Chemical Exchange 
Saturation Transfer) agents named LipoCEST and it is an emerging area of research to develop new 
highly efficient CEST agents. There are several reports of the application of paramagnetic lanthanide 
complexes doped in liposomes to develop a novel class of LipoCEST agents for MRI (Magnetic 
Resonance Imaging), which allow a marked sensitivity enhancement and thus significantly contribute 
to the development molecular imaging protocols.[33] Tm(III) and Dy(III) ions encapsulated in the 
liposomal cavity are used for developing LipoCEST agents.[34] Liposomes incorporating Gd(III)-
complexes have been successfully used in many in vivo MRI applications on animal models including 
the visualization of tumors either by passive[35] or active[36] targeting, detection of atherosclerotic 
plaques,[37] lymph nodes,[38] inflammation sites,[39] and visualization of myocardium infarcted areas.[40] 
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Figure 7: Some of lanthanide based complexes that were incorporated (either in liposomal cavity or on surface) 
into liposomes in the development of LipoCEST agents.[41] 
 
Lanthanide incorporated liposomes were also reported as selective biosensors. Elegbede et-al, 
in 2007, reported the application of lanthanide ion incorporated liposomes for selective recognition of 
carbonic anhydrase isozymes.[42] 
Liposomes have been used for in vivo drug delivery. For the necessary evaluation of the 
biodistribution of  liposomes as drug carriers, lanthanide complexes (eg Eu(III)) were incorporated as 
alternative to the conventional fluorophores and radiolabeled tracers (14C, 1H).[43]  
 
3.2 Outline of the chapter 
This chapter describes the design, synthesis and applications of amphiphilic lanthanide 
complexes embedded in liposome surfaces. In the first part of this chapter (section 3.3), synthesis and 
embedding of an amphiphilic Tb(III) complex into liposomal surface and its potential applications as  
reporter for physiological temperature change are discussed. The second part of this chapter (section 
3.4) summarizes attempts to use lanthanide based complexes as reporter dye non-covalently co-
embedded with analyte binding sites in nano-sized vesicular membranes. 
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3.3 Temperature responsive phosphorescent small unilamellar vesicles1 
3.3.1 Introduction 
Temperature is a fundamental physical property of matter important in everyday life and 
scientific and industrial applications. The methods to measure temperature can be divided into two 
main techniques: contact thermometry and non-contact thermometry. Contact methods include 
thermocouples, thermistors, and resistance temperature detectors (RTDs), whereas non-contact 
methods often use the spectral emittance of a material for readout. [44] 
Non-contact optical techniques have various advantages in terms of sensitivity and real-time 
monitoring over a wide range, from femtosecond to second.[45] Among the available optical methods, 
infrared thermometers that use the principle of blackbody radiation are flexible and easy to use, but 
can only measure the temperature of surfaces, thus limiting their applications. [46]Therefore 
luminescence based optical sensors have attracted much attention, because of their fast response, high 
spatial resolution, accurate usability even in strong electromagnetic fields [47] and safety of remote 
handling.[48] Such sensing probes use appropriate luminophores ranging from polycyclic aromatic 
hydrocarbons to metal complexes.[45] Temperature sensitive probes were incorporated into nanogels 
for intracellular thermometry,[49] and in sensor films or thermo-sensitive polymers to allow spatially 
resolved temperature imaging.[50] 
Recently lanthanide ion (Eu3+ and Tb3+) complexes have been used for optical sensing of 
temperature.[47, 50-51] The use of lanthanide complexes has several advantages over organic 
luminophores: (a) they have long emission wavelengths, (b) lanthanide emissions are Laporte 
forbidden and are therefore characterized by very long luminescence lifetimes, which is useful for 
applications in biological media; (c) 4f electrons of the lanthanides are highly shielded from the 
chemical environment by the 5s and 5p orbitals thus making them environment insensitive. Among 
the tripositive lanthanides, typically Eu3+ based complexes have been used as optical temperature 
sensors, while Tb3+ complexes are less explored. One reason is their smaller luminescence 
dependence on temperature.[52] However, the longer luminescence lifetime of the Tb3+ ion compared 
to Eu3+ make terbium complexes the favored system for the lifetime based optical sensors of 
temperature.[53] Having this in mind we considered using Tb3+ complexes as probes for optical sensing 
of temperature. By embedding the complex in different phospholipid based membranes we obtain 
reversible thermosensitive small unilamellar vesicles with an adjustable temperature range. Their 
luminescence is not affected by biological background fluorescence. 
 
 
                                                            
1 Temperature responsive phosphorescent small unilammelar vesicles; M. Bhuyan, B. Koenig (manuscript under 
preparation) 
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3.3.2 Results and discussions 
3.3.2.1 Synthesis of amphiphilic Tb(III) complex 
The DTPA based amphiphilic Tb(III) complex was synthesized as shown in Scheme 1. Since 
the 4f electrons are well shielded by the 5s and 5p orbital, lanthanides depend on a sensitizer or 
antenna to show luminescence (Figure 8). The energy transfer between the excited triplet state of the 
sensitizing ligand and the emitting level of the Tb(III) ion  is described by the Dexter mechanism[54] 
We have chosen  tryptophan  as a known sensitizer for the Tb(III)-ion. Detailed experimental 
procedures and analytical data of the prepared compounds are provided in the Experimental and 
Supporting data section.  
 
 
 
Scheme 1: Synthesis of Tb-1. (a) DCM, (Boc)2O, NEt3 [quantitative yield]; (b) DMF, 1-bromooctadecane, NaH 
[Yield: 93%]; (c) DCM, trifluoroacetic acid [Yield: 95%]; (d) DMF, CHCl3, 40°C, 24h [Yield: 55%]; (e) 
CH3OH, Tb(CF3SO3)3, 24h [Yield: 98%]  
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Figure 8: Energy Diagram of Tb(III) complexes with sensitizing ligand 
 
3.3.2.2 Preparation of the Tb(III) containing vesicular systems (LNT) 
Luminescent nanosized vesicular systems (LNT) with embedded Tb3+ complexes were 
prepared  following the previously reported film-hydration method.[55] The multilamellar vesicles 
were extruded through definite filters to get unilamellar vesicles of 90-100 (±5) nm in size. We have 
used different commercially available phospholipids for the preparation of LNT 1-7 (Table1). 
 
 
 
Figure 9: [Left] Schematic representation of LNT; [Right] excitation and emission spectra of LNT [excitation 
spectra: Tb(III) complex (5%)+DSPC) vesicle at  25°C, conc. of Tb(III) = 5 x 10−6 M; emission spectra: (a) 
[Tb(III) complex (5%)+DSPC] vesicle at 25°C , conc. of Tb(III) = 5 x 10−6 M, (b) [Tb(III) complex 
(5%)+DOPC] vesicle at  25°C, conc. of Tb(III) = 5 x 10−6 M, (c) Tb(III) complex at 25°C, conc. of Tb(III) = 1 x 
10−4 M] 
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Table 1: Composition, characterization and summary of applicability of prepared LNTs. 
 
Luminescent 
Vesicle 
Phospholipids 
used[56] 
Tm[a]
(°C)[56-
57] 
Size of 
Vesicles 
(nm)[b] 
Effective  
Range 
(°C) 
Most Sensitive 
Range  
(°C)[c] 
Sensitivity 
(% °C-1)[c] 
 
LNT1 
 
 
18:0 PC (DSPC) 
 
55 
 
95  
 
0-60 
 
25-55 
 
−3.5 
LNT2 16:0 PC (DPPC) 
 
41 98  0-40 20-40 −3.0 
LNT3 14:0 PC (DMPC) 
 
23 95  0-25 10-23 −4.2 
LNT4 DSPE-PEG350 
 
̴ 60 90  0-60 25-55 −1.8 
LNT5 
 
 
LNT6 
 
 
LNT4[c] 
+ BSA 
18:1c9 PC (DOPC) 
 
 
PC(18:0/14:0) 
(SMPC) 
 
DSPE-PEG350 
 
−20 
 
 
30 
 
 
̴ 60 
92  
 
 
95 
 
 
93  
n. a. 
 
 
0-30 
 
 
0-60 
n. a. 
 
 
15-30 
 
 
25-55 
n. a. 
 
 
-2.8 
 
 
−1.4 
 
 
 [a] Tm= phase transition temperature of lipids; [b]Z-average(d. Nm.) with s.d.= ±5; [c] the most sensitive 
temperature range and sensitivity per °C are based on the temperature dependent lifetime measurements carried 
out in HEPES buffer at pH 7.4, [c] the probable nonspecific interaction of the constituent lipids with protein 
(BSA)[58] are minimised by shielding the vesicular surface by using DSPC-PEG350 having oligoethylene glycol 
residues attached to its polar head groups  
 
The emission intensity of lanthanide complexes depend on their concentration. Due to 
clustering of the lanthanide ions a high concentration cross relaxation can lead to non-radiative decay 
from the 5D3 to the 5D4 level of a neighbouring ion.[59] Therefore several different concentrations of 
Tb-1 were used in the lipid membranes and in terms of emission intensity, 5 mol% of Tb-1 with 
respect to the used lipids is the most suitable condition for these systems. 
All vesicles (LNT) containing the Tb3+ complex exhibit a phosphorescence emission intensity 
at 488, 545, 584, 620 nm, which corresponds to the electronic transition from the 5D4 state to 7F3, 7F4, 
7F5, 7F6 states of the Tb3+ ions. However, at 25°C, the emission intensity is significantly different for 
LNT1 (DSPC lipids, Tm=55 °C) and LNT5 (DOPC lipids, Tm= −20°C), which indicates that the 
phase transition temperature of the lipids affects the emission intensity (Figure 9). 
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3.3.2.3 Temperature dependent measurements 
The temperature dependent emission intensity and lifetime measurements of the vesicular 
systems LNTs were carried out in HEPES buffer at pH 7.4. All vesicles show a decrease in their 
emission intensity with increase in temperature and each system shows more than 85% decrease in 
luminescence intensity around the transition temperature of the constituent lipid used (Figure 10 and 
11).  
 
  
 
Figure 10: [Left] Temperature dependence of emission intensity measurements for LNT3 (conc. of Tb(III) = 5 
x 10−6 M); [Right] Reversibility of LNT3 in the measured temperature range  
 
 
 
Figure 11: [Left] Temperature dependence of emission intensity measurements for LNT2 (conc. of Tb(III) = 5 
x 10−6 M); [Right] Photograph of change in emission intensity of LNT2 (conc. 2mM, conc. of Tb(III) = 1x 10−4 
M) with temperature. Phosphorescence was recorded at different temperature by using a UV table (ex = 315 
nm) 
 
The emission changes for the vesicular systems, LNT1-6, are reversible within the measured 
temperature range, as shown in Figure 10 (right) for LNT3. 
However, the emission intensity based measurements often suffer from concentrations of 
sensors or drifts of the optoelectronic systems (lamps and detectors),[51c] whereas decay lifetime based 
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data are free from these drawbacks and are more reliable. The synthesised luminescent vesicular 
systems, LNT, also show reversible change in decay lifetime with change in temperature. The 
luminescence decay vs. time curve follows first order exponential decay at every measured 
temperature (figure 12) and the average lifetime (τ) is determined by equation 1, 
 
ݕ ൌ ܣଵ כ expሺെ ݔ⁄߬ ሻ ൅ ݕ଴                                              (1) 
 
where, y= lifetime at time x; y0=initial lifetime; x= time; τ =1/(decay constant), A1= pre 
exponential factor. 
The lifetime vs. temperature plot shows that for every system, average lifetime (τ) decreases 
with increase in temperature and the system shows high sensitivity around the phase transition 
temperature (Tm) of the constituent lipid (Figure 12). Thus the most sensitive temperature range for 
these nano systems can be tuned by changing the constituent lipids. Table 1 shows the most sensitive 
temperature range and sensitivity per °C in that range for each particular system. 
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Figure 12: [Left] Luminescence decay vs. Time plot for LNT2 at 0°C; [Right] Average lifetime (± s.d.) (ms) 
vs. Temperature (°C) plot for LNT3 
 
The luminescence intensity and lifetime of lanthanides can be affected by many factors. The 
overall decay rate constant of the luminescence level can be expressed by the following equation,[60] 
with ݇௥ is the radiative rate constant and ݇௡௥ and ݇௡௥ሺܶሻ are the non-radiative temperature 
independent and temperature dependent decay rate constants.  
 
݇ ൌ ଵఛ ൌ ݇௥ ൅ ݇௡௥ ൅ ݇௡௥ሺܶሻ                                        (2) [60] 
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The non-radiative transition consists of the vibrational excitation, back energy transfer (BET) 
to triplet excited state of the sensitizer attached from the 5D4 state of Tb(III) and the concentration 
quenching. Temperature-dependence of the decay rate constant or ݇௡௥ሺܶሻ is expected for the 
vibrational excitation and BET in the nonradiative transition from the 5D4 level of the terbium(III) 
ion.[52a] Decrease in luminescence intensity can be related to both the aforementioned factors, while 
decrease in luminescence lifetime is dependent only on the energy dissipation from the 5D4 state of 
Tb(III). These facts give a rationale for the sensitivity of LNT near the transition temperature of the 
lipid. The constituent phospholipids are in a tightly packed gel phase below the transition temperature 
(Tm)[61] and this leads to  deactivation of vibrational excitation and hence a longer lifetime of the 
embedded Tb(III) ion. Near or above the phase transition temperature, the lipid bilayers are more or 
less in the liquid crystalline phase[61c] with higher chain mobility of the constituent lipids consequently 
leading to drastic decrease in the luminescence lifetime by vibrational dissipation of energy from the 
5D4 state of the Tb(III) ion. 
 
 
 
Figure 13: Schematic representation showing differences in gel and liquid crystalline phases in phospholipids 
bilayers with embedded amphiphilic Tb(III) ion 
 
Above Tm of the corresponding lipids, the nano systems show negligible sensitivity towards 
increase in temperature. 
The fully PEGylated vesicule, LNT4, shows reversible change in emission intensity with 
temperature. However, for a given wavelength, the intensity vs. temperature plot is convex for the 
non-PEGylated vesicles, while it is concave for the completely PEGylated vesicular system, LNT4, 
(Figure 14). The difference in the nature of the plot can be attributed to increased chain mobility of 
the PEGylated lipids compared to the non-PEGylated ones in gel, intermediate as well as in the fluid 
phase as shown by Belsito et al using spin-label ESR measurements.[62] 
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Figure 14: [Left] Temperature dependence of emission intensity measurements for LNT4 (conc. of Tb(III) = 5 
x 10−6 M); [Right] Lifetime reversibility of LNT4 in the measured temperature range     
 
The temperature dependent luminescence changes of  LNT4 is not affected by the presence of 
bovine serum albumin (BSA) (Table 1), which indicates potential applications of these kinds of 
systems in biological medium.  
 
 
  
Figure 15: Photographs of the luminescent membranes at different temperature. The letters were written in a 
glass surface by using a solution of LNT1 (2mM). The letters were dried by blowing a stream of air. 
Phosphorescence was recorded at different temperature by using a UV table (ex = 315 nm). 
 
3.3.3 Concluding remarks 
 In summary, we have developed a novel approach towards luminescence thermometry by 
using a self assembly of lipids and amphiphilic Tb(III) complexes. Such systems are useful for 
sensing and imaging of physiological temperatures by changes in their phosphorescence intensity and 
lifetime. The most sensitive temperature and sensitivity per °C can be tuned by merely playing with 
the phase transition temperature of the constituent lipids. As a proof of this principle, we have used 
lipids with different phase transition temperatures resulting in vesicles with their highest sensitivity in 
different temperature ranges. Membranes can be processed, e.g. by simple spreading on a glass 
surface without losing their sensing ability. Since Tb(III) has a very long luminescence lifetime, 
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interference of background fluorescence arising from proteins or cells can be avoided by delayed 
readout.  
 
3.3.4 Experimental Section 
 
General methods and material 
All reagent-grade chemicals were used without purification unless otherwise specified. 
Diethylenetriaminepentaacetic dianhydride (DTPAA), tryptamine, Tb(CF3SO3)3 were obtained from 
Aldrich and used as received.  
 
NMR Spectra 
NMR spectra were measured with Bruker Avance 600 (1H: 600.1 MHz, 13C: 150.1 MHz, T = 300 
K), Bruker Avance 400 (1H: 400.1 MHz, 13C: 100.6 MHz, T = 300 K), Bruker Avance 300 (1H: 
300.1 MHz, 13C: 75.5 MHz, T = 300 K). The chemical shifts are reported in δ [ppm] relative to 
external standards (solvent residual peak). The spectra were analysed by first order, the coupling S-1 
constants are given in Hertz [Hz]. Characterisation of the signals: s = singlet, d = doublet, t = triplet, q 
= quartet, m = multiplet, br = broad, dd = double doublet. Integration is determined as the relative 
number of atoms. The solvent used is reported for each spectrum. 
 
Mass Spectra 
Mass spectra were obtained with Varian CH-5 (EI), Finnigan MAT 95 (CI; FAB and FD), Finnigan 
MAT TSQ 7000 (ESI). Xenon serves as the ionisation gas for FAB. 
 
IR Spectra 
IR spectra were recorded with a Bio-Rad FTS 2000 MX FT-IR and Bio-Rad FT-IR FTS 155. 
 
Absorption Spectroscopy 
Absorption were recorded on a Varian Cary BIO 50 UV/VIS/NIR Spectrometer with temperature 
control by use of a 1 cm quartz cuvettes (Hellma) and aqueous buffered solution (HEPES 25 mmol, 
pH = 7.4). 
 
Emission Spectroscopy 
 Luminescence intensity and lifetime measurements were performed with aqueous buffered solution 
(HEPES 25 mmol, pH = 7.4) in 1 cm quartz cuvettes (Hellma) and recorded on a Varian ‘Cary 
Eclipse’ fluorescence spectrophotometer with temperature control. 
 
 
3. Phosphorescent Small Unilamellar Vesicles with embedded Amphiphilic Lanthanide complexes 
 
 
   94 
Dynamic light scattering 
Photon correlation spectroscopy (PCS) measurements were performed on a Malvern Zetasizer 3000 at 
25°C using 1cm disposable polystyrene fluorescence cuvettes (VWR). Three subsequent 
measurements of 60 s each were performed for each sample. Data analysis was performed using the 
Malvern PCS software. 
 
 
Synthesis of compound 1-Boc: To a yellow suspension of tryptamine (1.00 g, 6.24 mmol) in 1, 4-
dioxane (5 mL) was added Et3N (1.80 mL, 12.9 mmol). A solution of (Boc)2O (1.50 g, 6.87 mmol) in 
1,4-dioxane (5 mL) then was added to the reaction mixture. This mixture was stirred for 1 h and the 
resulting yellow solution was concentrated to dryness under reduced pressure. The crude residue was 
purified by coloumn chromatography on silica gel (30% ethylaceate in petrolether) to give the desired 
1-Boc amine as an amorphous white solid (yield: quantitative). 
1H NMR (300 MHz, CDCl3) = 1.54 (s, 9H), 3.00 (t, 2H), 3.53 (d, 2H), 4.85 (br, s, 1H), 6.97 (s, 1H), 
7.15-7.28 (m, 1H), 7.37 (d, 1H), 7.65 (d, 1H), 8.68 (br, 1H) ppm 13C NMR (75 MHz, CDCl3) =14.29, 
21.16, 25.86, 28.57, 41.10, 60.60, 67.12, 111.45, 112.73, 118.80, 119.28, 121.99, 122.37, 127.44, 
136.56, 156.33, 171.49 ppm MS (EI MS) m/z = 260.31 [M+] (Calc. =260.33) 
 
Synthesis of compound 2: To a stirred suspension of NaH (60% dispersion in mineral oil, 0.05g, 
2.37mmol) in THF (5mL), was added a solution of 1-Boc (0.50 g, 1.97mmol) in THF (5mL). After 
stirring at room temperature for 10min, 1-bromooctadecane (0.76g, 2.37mmol) was added, and 
stirring was continued for 3h. Water was then added, and the mixture was extracted with ethylacetate. 
The organic layer was washed with brine, dried over MgSO4, and concentrated under vacuum. The 
residue was chromatographed on silica gel, eluting with 10% ethylacetate in petrolether to give 2-Boc 
as an amorphous solid (yield: 93%). 
1H NMR (300 MHz, CDCl3) = 0.93 (t, 3H), 1.30 (s, 28H), 1.48 (s, 9H), 1.86 (t, 2H), 2.98 (t, 2H), 3.50 
(t, 2H), 4.08 (2H), 6.96 (s, 1H), 7.10-7.16(m, 1H), 7.21-7.27 (m, 1H), 7.33 (d, 1H), 7.62(d, 1H) ppm. 
13C NMR (75 MHz, CDCl3) =14.20, 22.77, 25.81, 27.12, 28.25, 28.85, 29.53, 29.57, 32.00, 44.96, 
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65.84, 109.34, 111.50, 118.73, 121.47, 125.69, 127.93, 136.42, 155.93, 161.00, 177.52 ppm. MS (EI 
MS) m/z = 512.7 [M+] (Calc. =512.81) 
 
Synthesis of compound 2-H: Compound 2 (0.54g, 1.78mmol) was dissolved in dichloromethane 
(5ml). Trifluoroacetic acid (2ml 24.9mmol) was added and the solution was stirred for 6h. The solvent 
was then evaporated of under vacuum pressure. The colourless oil obtained, which is a 
trifluoroacetate salt was then dissolved in methanol: water mixture (1:1) and passed through basic ion 
exchange resin. The solvent was removed and the compound 2 was recovered as an amorphous white 
solid (yield: 95%). 
1H NMR (300 MHz, CDCl3) = 0.82 (t, 3H), 1.20 (s, 28H), 1.68 (t, 2H), 2.86-2.96 (m, 4H), 3.96(t, 2H, 
6.95-7.05 (m, 3H), 7.20 (d, 1H), 7.48(d, 1H) ppm. 13C NMR (75 MHz, CDCl3) =14.59, 23.81, 27.59, 
28.01, 30.66, 31.34, 33.23, 42.16, 47.19, 110.61, 111.34, 119.87, 122.77, 127.34, 129.21, 138.20 
ppm. MS (EI MS) m/z = 412.7 [M+] (Calc. =412.6) 
 
Synthesis of compound 4: Diethylenetriaminepentaacetic dianhydride (1) (0.12g, 0.35 mmol) was 
dissolved in 5 mL of dry DMF. Compound 2 (0.29 g, 0.69 mmol) was dissolved in 5 mL of dry 
chloroform; added drop wise to the solution and the mixture was left to stir at 40 °C for 24 h. On 
cooling to room temperature, a precipitate was formed, which was collected. The white solid was 
stirred in water at ~ 80 °C for one hour, isolated, stirred in diethyl ether for one hour and isolated. The 
crude product was recrystallised from 50:50 chloroform:methanol. On cooling a white solid was 
formed, which was isolated by filtration, washed with diethyl ether and dried under vacuum (yield: 
55%). 
1H NMR (400 MHz, CD3OD:CDCl3= 1:1) = 0.84 (t, 6H), 1.22 (s, 60H), 1.69 (t, 4H), 2.89-2.99 (m, 
12H), 3.33-3.47 (m, 18H), 3.95 (t, 4H), 6.88(s, 2H), 6.99(m, 2H), 7.09( t, 2H), 7.22(d, 2H), 7.52(d, 
2H) ppm 13C NMR (100 MHz, CD3OD:CDCl3= 1:1) =14.49, 23.21, 27.29, 28.01, 30.34, 31.12, 
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32.98, 42.02, 47.04, 50.10, 53.33, 55.08, 56.72, 58.59, 110.59, 111.34, 119.87, 122.35, 127.04, 
129.01, 138.24 ppm MS (EI MS) m/z = 1183.1 [M+] (Calc. = 1182.7) max (KBr disc): 3303b (OH), 
2919m, 2848m (CH); 1625w (C=O); 1468w, 1373m, 1236m, 1098w 
N
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N
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N
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O O
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Synthesis of compound Tb-1: Compound 4 (0.1 g, 0.08 mmol) was dissolved in approximately 10 
mL of a hot 1:1 CHCl3/CH3OH mixture. Tb(CF3SO3)3 (0.05 g, 0.09 mmol,), dissolved in 2 mL 
CH3OH, was added and the mixture was stirred at 50 °C for 8 hours. The solvent was removed under 
vacuum and the white solid obtained was washed with water and dried (yield: 98%). MS (EI MS) m/z 
= 1339.1 [M+] (Calc. = 1340.8) 
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3.3.5 Supporting Data 
 
1H and 13C NMR of the synthesised compounds: 
 
 
1H NMR of compound 2 (300MHz, CDCl3) 
 
 
13C NMR of compound 2 (75MHz, CDCl3) 
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1H NMR of compound 4 (400MHz, CD3OD:CDCl3= 1:1) 
 
 
Dynamic light scattering measurements: 
 
 
 
 
 
 
Figure 16: Dynamic light scattering measurements for LNT3 
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Figure 17: Dynamic light scattering measurements for LNT4 
 
 
 
Temperature dependent emission intensity and lifetime measurements: 
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Figure 18: Change in lifetime (± s.d.) (ms) with change in temperature [left: LNT4, right: LNT2] 
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Figure 19: Photograph of change in emission intensity of LNT1 (conc. 2mM, conc. of Tb(III) = 1x 10−4 M ) 
with temperature. Phosphorescence was recorded at different temperature by using a UV table (ex = 315 nm).  
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3.4 Nano-sized Vesicular Membranes with Amphiphilic Binding Sites and Lanthanide 
complex with Delayed Luminescence as Reporter Dye 
3.4.1 Introduction 
Chemosensors, typically small abiotic molecules that can recognize the presence of a suitable 
analyte, have two main components: a recognition site that binds to the analyte and a readout system 
that signals the binding event.[63] Although for the last two decades considerable attention in 
chemosensors was propelled by potential applications in biology, medicine, analytical chemistry, 
environmental and material science,[64] the implementation of sensing probes in functional devices 
without the loss of sensitivity is still very challenging. For selective recognition of biologically 
relevant anions, transition metal complexes with vacant coordination sites are widely used as the 
recognition site and different chromophoric or luminophoric organic dyes are typical signaling units. 
The signaling unit can either be directly attached to the recognition site by covalent bond formation or 
it can be non-covalently attached as a part of a kinetically labile receptor complex and can easily be 
replaced by a suitable analyte. The later phenomenon is the basic principle of indicator displacement 
assays. Apart from these strategic approaches towards guest binding, which have the drawback of the 
difficult, laborious synthesis or non reversibility (indicator displacement assays), recently another 
alternate approach has been reported, which involves non-covalent co-embedding of the amphiphilic 
guest binding site and the reporter dye in a modulated vesicular membrane.[31b] This approach has 
decreased the laborious effort for the synthesis of luminescent chemo sensors enormously and the 
system has been found to be quite effective for the detection of different biologically relevant 
analytes. However the usual reporter dyes that have been used for decades for the detection of 
biologically important analytes are typically organic dyes that have the limitation of having emission 
life times in nanosecond range, whereas those of biological matrix are typically in the submicrosecond 
range.[5a] Hence these are practically not very effective as a part of an analytical tool to be used in 
complex biological medium. The use of extremely long luminescent lifetime of lanthanide based 
probes (for europium and terbium complexes life time is in millisecond range) can effectively 
overcome this limitation. Considering these advantages of lanthanide ions over organic dyes, we 
planned to use lanthanide based complexes as reporter dyes, which can be non-covalently co-
embedded with analyte binding sites in nano-sized vesicular membranes. 
 
3.4.2 Results and Discussions 
3.4.2.1 Anion recognition site and reporter dye 
The molecules that are used for the current studies are shown in Figure 1. 
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Figure 20: Molecules embedded in the vesicular membrane for anion recognition 
The amphiphilic Zn(II)-bis cyclen complex (Zn-BC-1) was used as the guest recognition site. 
The Tb(III) complexes (Tb-1, Tb-2) were used as reporter dyes. However, as mentioned in part1 of 
this chapter (Chapter 3, Pat 1), like other lanthanides, Tb(III)  depend on sensitizer or antenna 
molecules to show luminescence. Hence the tryptophan based modified amphiphile (Trp-1) was also 
incorporated into the vesicular membrane as antenna for Tb-2. 
 Synthesis of Tb-1 is reported in Part1 of this chapter. The guest binding site Zn-BC-1 and the 
reporter molecule Tb-2 along with antenna Trp-1 were synthesized following previously reported 
procedures.[3a, 65] 
3.4.2.2 Vesicle Preparation and Characterization of vesicle dispersions 
The liposomes with embedded Tb(III)complex and sensitizer were prepared  following the 
previously reported film-hydration method.[55] The multilamellar vesicles were extruded through 
definite filters to get unilamellar vesicles of 90-100 (±5) nm in size. 
The modulated vesicular receptors (LV-1, LV-2, and LV-3) with phospholipid bilayer-
embedded receptor and lanthanide complex as reporter dye were prepared following our previously 
reported procedure.  
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These are prepared from a mixture of commercially available synthetic phospholipid 1,2-
distearoyl-sn-glycero-3-phosphocholine (DSPC), DSPC-PEG350, amphiphilic Zn(II)-cyclen 
complexe (Zn-BC-1), and lanthanide complex (Tb-1) by the well-established film-hydration 
method.[55] The resulting multilamellar vesicles (MLVs) were homogenized by extrusion to yield 
small unilamellar vesicles (SUVs) of a defined size of 80–100 nm. 
The particle size, particle number and sample dispersity of the prepared vesicle dispersions were 
determined by dynamic light scattering (DLS) and the average hydrodynamic diameter of the 
functionalized vesicles was found to range from 80 to 90(±5) nm (Table 2). Generally, homogenized 
SUV dispersions are assumed to be free of impurities and thus no further purification is required. All 
prepared vesicle dispersions were stored as buffered aqueous solutions at 6°C and used within 2 
weeks  
3.4.2.3 Enhancement of lanthanide luminescence by self assembly 
 It is reported that lanthanide complexes can be sensitized by intermolecular energy transfer 
by a non-covalently bound sensitizer co-embedded in a micellar medium[3a] or gel matrix.[3b] 
Therefore the synthesized lanthanide complex Tb-2 along with antenna Trp-1 were incorporated into 
liposomes to check the energy transfer in different liposomal surfaces.   Based on phase transition 
temperatures (Tm), we have chosen DSPC (Tm= 55°C) and DOPC (−20°C) as phospholipids for two 
different liposomal surface. For similar concentrations of Tb(III) ion(Tb-2) and sensitizer (Trp-1) we 
could observe two drastically different emission maxima in these two different liposomal surface. 
Again from the Part 1 of this chapter, we know that the emission intensity observed for Tb-1 with 
covalently attached sensitizer molecule in DSPC and DOPC lipids are also significantly different. 
However the emission maxima for Tb-1 embedded in DOPC lipid based liposome is not comparable 
with that for Tb-2 and Trp-1 co-embedded in DOPC lipid based liposome. Since the sensitized 
emission of the lanthanide complex depends on the distance between the metal cation and the 
sensitizer,[5a] the comparisons of the two different DOPC lipids based liposomes with Tb-1 and Tb-2 
suggest that the packing of the complex molecules in DOPC liposomes at room temperature with very 
low phase transition temperature (−20°C) are similar to the solution phase. 
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Figure 21: Emission spectra of (a) Tb-1 and (b) Tb-2 with Trp-1 in DOPC lipid based liposomes 
3.4.2.4 Attempts to use lanthanide based complex as reporter dye: Experimental 
observations 
The synthesized lanthanide complex (Tb-1) was co-embedded as reporter dye with 1, 4, 7, 
10-tetraazacyclododecane (cyclen)–zinc (II) complex (Zn-BC-1) as binding site in DSPC+DSPC-
PEG350 vesicle. Upon excitation at 285nm the vesicle LV-1 with phospholipid bilayer-embedded 
Zn-BC-1 as receptor and Tb-1 as reporter dye exhibit strong phosphorescence emission with four 
emission maxima at 490, 545, 585 and 620nm. These can be assigned to respective transitions from 
5D4 excited-state to the ground state 7FJ (J = 3, 4, 5, 6). The vesicular solution was titrated with 
oxoanions such as PPi and O-phospho-L-serine.  In the presence of increasing amounts of phosphate 
anions, such as pyrophosphate (PPi) or phosphoserine (pSer), this emission intensity was decreased. 
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Figure 22: Change in emission intensity of LV-2 with increasing concentration of O-phospho-L-Serine 
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Table2: Molar composition and size of the synthesized vesicles 
Vesicle Molar composition (+analyte) Size(nm) 
LV-1 Tb-1/DSPC/DSPC-PEG350/Zn-BC-1 
1: 11.2: 8.8: 1 
89 ± 5 
LV-1+ BSA+ p-Ser Tb-1/DSPC/DSPC-PEG350/Zn-BC-1 
+BSA+p-Ser 
1: 11.2: 8.8: 1+ 1eq BSA+2eq p-Ser 
------ 
LV-2 Tb-1/DSPC/DSPC-PEG350 92 ± 5 
 1: 11.7: 9.3  
LV-2+ BSA Tb-1/DSPC/DSPC-PEG350+BSA 
1: 11.7: 9.3+ 2eq BSA 
95 ± 5 
LV-2+ ɑ-Casein Tb-1/DSPC/DSPC-PEG350+BSA 
1: 11.7: 9.3+ 2eq ɑ-Casein 
117 ± 5 
LV-2+ ɑ-Casein (70% 
dephosphorylated) 
 
LV-3 
 
LV-4 
Tb-1/DSPC/DSPC-PEG350+BSA 
1: 11.7: 9.3+ 2eq ɑ-Casein 
(70% dephosphorylated) 
Tb-2/DSPC/Trp-1/Zn-BC-1 
3:43:1:3 
Tb-2/DSPC/Trp-1 
3:46:1 
118± 5 
 
 
90± 5 
 
95± 5 
 
Similarly lanthanide complex Tb-2 along with Trp-1 and Zn-BC-1 were incorporated into 
DSPC vesicles (LV-3). The vesicular solution was titrated with PPi. With increasing amount of PPi, 
the emission intensity corresponding to Tb(III) decreases and we could observe up to 25% decrease in 
intensity upon addition of 6eq of PPi. 
The change in emission intensity of Tb-1 upon phosphate binding to Zn-BC-1 is also 
observed in presence of BSA. As a control experiment Tb-1 was embedded in a vesicular membrane, 
LV-2, without any co-embedded receptor binding site and analysed for phosphate binding. With the 
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increasing amount of phosphate anions such as phosphoserin (pSer) there is some change in emission 
intensity. A similar control experiment was done with Tb-2.  Tb-2 with Trp-1 were embedded into 
DSPC vesicles without Zn-BC-1 to check if the Tb(III) complex has some interaction with the added 
analyte (LV-4). With increase in concentration of PPi (upto 6eq) we could observe some change 
(10%) in emission intensity (figure 23), which shows that the neutral Tb complex interacts with the 
oxo-anion. 
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Figure 23: Change in emission intensity of LV-4 with increasing concentration of PPi. (Emission change at 
only one wavelength, 545nm, is shown here) 
Again, the prepared Tb-1 embedded vesicular system, LV-2 was found to be not responsive 
to an increasing amount of added BSA. However, with ɑ-S1-Casein and dephosphorylated ɑ-S1-
Casein the results are found to inconclusive. In both cases with increasing amount of casein, there is a 
change in the terbium emission intensity.  
3.4.3 Concluding remarks 
In conclusions, we have synthesized neutral Tb(III) based complexes to explore applications 
of these complexes as reporter dye co-embedded  with amphiphilic binding sites in a self-assembled 
vesicular membrane for the recognition of biologically relevant anions. Although in a control 
experiment, we could observe minor interactions of these neutral complexes with the added oxo-
anions, co-embed complexes in vesicular membranes with amphiphilic Zn(II) complex as receptor 
molecule showed decrease in luminescence with increasing amount of oxo-anions as added analytes. 
These observations suggest a potential application of the complexes in the recognition of analytes. 
Future research includes modifying the structure of the Tb(III) complex to minimize its interaction 
with analytes. 
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Summary 
Chapter 1 of this thesis deals with synthesis of a series of water soluble bis- and tetrakis-Zn 
(II)-cyclen complexes with rigid structures and their applications in recognition of biologically 
relevant analytes. Boc-protected 6-chloro-1, 3, 5-triazine-bis cyclen was coupled to several aryl and 
alkyl moieties by using Suzuki cross coupling in moderate to high yields and subsequently converted 
into the corresponding bis- or tetrakis-Zn(II)-cyclen complexes. Some of the arene substituted 
modified bis- and tetra-Zn(II)-cyclen complexes were luminescent and those were studied by 
absorption and luminescence spectroscopy for their response to phosphate anions at physiological 
conditions.  Also, tetra-Zn(II)-cyclen complexes were found to have significant affinity to genetically 
encodable oligo-aspartate and glutamate sequences (D4- and E4-tag). The rigid structures of the 
compounds enhance the electronic coupling between the metal complex binding site and the reporter 
dye leading an increased anion binding response in homogeneous aqueous solution. 
Chapter 2 is a report of synthesis and potential applications of rigid amphiphilic molecular 
receptors, bioconjugates and radiopharmaceuticals based on metal-cyclen complexes via click 
chemistry. Using bioorthogonal click reaction, we have synthesized biotinylated Zn(II)-bis-cyclen and 
showed its promising application in activity based proteomics. Cholesterol and long alkyl chain 
conjugated modified Zn(II)-cyclen complexes were synthesized for a template guided cooperative 
self-assembly of nucleotides at interfaces fabricated by combination of self-assembled monolayer 
technique (SAM) and Langmuir Blodgett technique (LB). These complexes can act as binding sites at 
interfaces prepared by a combination of SAM and LB film approaches or in vesicular surfaces. 
Investigations of the binding properties of these new amphiphilic complex embedded surfaces are in 
progress. 
Chapter 3 involves design, synthesis and applications of amphiphilic lanthanide complexes 
embedded in liposomal surface. We have synthesized amphiphilic Tb(III) complex and embedded into 
liposomal surface. This phosphorescent nanosystem has a potential application as a reporter for 
change in physiological temperature. We have also attempted to use lanthanide based amphiphilic 
complexes as reporter dyes non-covalently co-embedded with analyte binding sites in nano-sized 
vesicular membrane 
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Zusammenfassung 
Kapitel 1 dieser Dissertation befasst sich mit der Synthese von wasserlöslichen Bis- und 
Tetrakis-Zn(II)-Cyclen Komplexen mit starren Strukturen und deren Anwendung in der molekularen 
Erkennung von Analyten biologischer Relevanz. Boc-geschütztes 6-Chloro-1,3,5-Triazin-Biscyclen 
wurde per Suzuki-Kreuzkupplung in mittelmäßigen bis hohen Ausbeuten an verschiedene Aryl- und 
Alkyleinheiten geknüpft und davon ausgehend die jeweiligen Bis- oder Tetrakis-Zn(II)-Cyclen 
Komplexe hergestellt. Die Lumineszenten unter den Aren substituierten Bis- und Tetra-Zn(II)-Cyclen 
Komplexen wurden durch Absorptions- und Lumineszenzspektroskopie im Hinblick auf deren 
Antwort gegenüber Phosphationen unter physiologischen Bedingungen getestet. Es wurden außerdem 
Tetra-Zn(II)-Cyclen Komplexe entdeckt, die eine signifikante Affinität gegenüber genetisch 
kodierbare Oligoaspartat- und Glutamatsequenzen (D4- und E4-Tag) aufweisen. Die starren Strukturen 
der Substanzen verstärken die elektronische Kupplung zwischen der Metallkomplexbindungsstelle 
und dem Reporter-Farbstoff, was zu einem verbesserten Signal der Anionenbindung in homogener 
wässriger Lösung führt. 
Kapitel 2 beschäftigt sich mit der Synthese und der potentiellen Anwendung von starren 
amphiphilen molekularen Rezeptoren, Biokonjugaten und Radiopharmaka, die auf Metall-Cyclen 
Komplexen basieren und per „Click-Chemie“ synthetisiert wurden. Mittels der bioorthogonalen 
Click-Reaktion haben wir biotinylierte Zn(II)-bis-Cyclen Komplexe synthetisiert und ihre 
vielversprechende Anwendung in der aktivitätsbasierten Proteomik gezeigt. Cholesterin und mit 
langkettigen Alkylresten substituierte Zn(II)-Cyclen Komplexe wurden synthetisiert, um eine Templat 
gesteuerte kooperative Selbstorganisation von Nukleotiden an Grenzflächen zu erreichen, welche 
durch Kombination von selbstorganisierender Monoschicht (SAM) und Langmuir Blodgett Technik 
(LB) erzeugt wurden. Eine Anwendung dieser Komplexe ist der Einsatz als Bindungsstellen an 
Grenzflächen, die durch eine Kombination von SAM und LB Film Methoden oder in vesikularen 
Oberflächen entstehen. Die Bindungseigenschaften dieser neuen amphiphilen mit Komplexen 
funktionalisierten Oberflächen werden gerade untersucht.  
Kapitel 3 beinhaltet das Design, die Synthese und die Anwendungen von amphiphilen 
Lanthanidkomplexen, die in liposomale Oberflächen eingebettet sind. Wir haben Tb(III) Komplexe 
synthetisiert und in liposomale Oberflächen integriert. Dieses phosphoreszente Nanosystem hat eine 
potentielle Anwendung als Sensor für physiologische Temperaturänderungen. Weiterhin haben wir 
erreicht, Lantanid basierte amphiphile Komplexe als Reporter-Farbstoffe nichtkovalent zusammen mit 
Analytbindungsstellen in Vesikelmembrane im Nanomaßstab einzubetten. 
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Abbreviations 
abs 
 
Absolute 
 
HSQC  
 
 
heteronuclear single quantum 
coherence 
 
 
ADP 
 
 
Adenosine di phosphate 
 
IR Infrared  
 
ATP 
 
 
Adenosine tri phosphate 
 
LB Langmuir- Blodgett 
 
Boc 
 
 
tert-butyloxycarbonyl 
 
MeCN acetonitrile 
 
br 
 
 
broad 
 
MeOH methanol 
 
BSA 
 
 
Bovine Serum Albumin 
 
MLV multilamellar vesicle 
 
COSY 
 
 
Correlation spectroscopy 
 
MS Mass spectrometry 
 
CuAAC 
 
 
Copper catalyzed Azide Alkyne 
Cycloaddition 
 
MW Molecular weight 
 
DCM 
 
 
Dichloromethane 
 
NP Nanoparticle 
 
DFT 
 
 
Density Functional Theory 
 
NMR Nuclear Magnetic Resonance 
 
DIPEA 
 
 
Diisopropyl ethylamine 
 
o/n over night 
 
DLS 
 
 
Dynamic Light Scattering 
 
PEG polyethylene glycol 
DMF 
 
 
N.N-dimethylformamide 
 
PET 
 
Positron Emission Tomography 
 
DMPC 
 
1,2-dimyristoyl-sn-glycero-3-
phosphocholine 
 
PPi 
 
pyrophosphate 
 
 
DNA 
 
 
Deoxyribonucleic acid 
 
p-Ser O-phospho-L-serine 
DOPC 
 
 
1,2-dioleoyl-sn-glycero-3-
phosphocholine 
 
rt room temperature 
    DPPC 
 
1,2-dipalmitoyl-sn-glycero-3-
phosphocholine 
 
 
UV 
 
 
Ultraviolet 
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DSC 
 
 
 
Differential Scanning Calorimetry 
 
 
 
SAM 
 
 
 
self assembled monolayer 
 
 
DSPC 
 
 
1,2-distearoyl-sn-glycero-3-
phosphocholine 
 
 
SDS-PAGE 
 
 
sodium dodecyl sulfate 
polyacrylamide gel 
electrophoresis 
 
 
DSPE-
PEG350 
 
1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-
[amino(polyethyleneglycol)-350] 
(ammonium salt) 
SMPC 
 
1-stearoyl-2-myristoyl-sn-
glycero-3-phosphocholine 
 
 
 
DTPA 
 
 
 
diethylene triamine pentaacetic acid 
 
 
SUV 
 
 
small unilamellar vesicle 
 
ECL 
 
enhanced chemiluminescent 
 
TBTA 
tris-
(benzyltriazolylmethyl)amine 
 
 
eg 
 
 
for example 
 
TFA 
 
trifluoroacetic acid 
 
 
eq 
 
 
equivalents 
 
 
THF 
 
 
tetrahydrofuran 
 
 
ESI 
 
 
Electron spray ionization 
 
 
TLC 
 
 
thin layer chromatography 
 
 
HEPES 
 
 
4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid 
 
 
TMS 
 
 
trimethylsilyl 
 
 
HBTU 
 
 
O-(1-benzotriazolyl)-N,N,N',N'-
tetramethyluronium hexafluorophosphate 
 
 
 
Tm 
 
 
 
transition temperature 
 
 
HMBC  
 
 
heteronuclear multiple bond correlation 
 
 
Tp 
 
 
pre-transition temperature 
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NMR changes D. Mandal, P. Chadha, M. Laskar, M. Bhuyan, B. D. Gupta 
Tetrahedron Lett. 2007, 48, 2377 
doi: 10.1016/j.tetlet.2007.01.140 
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AWARDS AND 
ACHIEVEMNTS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Bavarian Research Scholarship, Germany  
(Bayerische Forschungs Stiftung) 
 
Degussa‐Evonik Scholarship, 
Germany 
 
Best poster Award in MTIC‐XII, IIT Madras, India 
 
Qualified in GATE’06, India 
GATE Rank: All India Rank 58; GATE Score: 508 
Total no. of students appeared: 4542 
 
Merit‐cum‐Means Scholarship, IIT Guwahati, India 
 
Fifth rank in the B.Sc. examination with distinction, 
Gauhati University, India 
 
2009‐2011 
 
 
2008‐2009 
 
 
Dec’07 
 
Feb’06 
 
 
 
Apr’04‐Apr’06 
 
Jul’03 
 
CONFERENCES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4th  International  Summer  School  “Supramolecular  Systems  in 
Chemistry and Biology”, Sept’11, Regensburg, Germany 
Rigid  Luminescent  BisZinc(II)–BisCyclen  Complexes  and  Non  Covalent 
Protein Labelling in Aqueous Solution(poster presentation) 
 
2nd  INDIGO  PhD  Research  Conference  and  Intensive  Course,  Oct’10, 
Regensburg, Germany  
 
3rd EuCheMS Chemistry Congress, Aug‐Sept'10, Nuremberg, Germany 
“Rigid Luminescent Zinc(II)­Bis­Cyclen Based Receptors  for Recognition 
of Phosphate Anions in aqueous solution” (poster presentation) 
 
2nd  German‐Indian  Symposium  on  Frontiers  of  Chemistry,  Sept’09, 
University of Leipzig, Leipzig, Germany 
“Luminescent  Zinc(II)Bis­cyclen  Receptors  in  Molecular  Recognition” 
(poster presentation) 
 
Vth  International  Symposium  Supramolecular  Systems  in  Chemistry 
and Biology, May’09, Kyiv, Ukraine 
“Zinc(II)­cyclen  Based  Receptors  for  The  Molecular  Recognition  of 
Phosphate Anions” (poster presentation) 
 
Modern Trends in Inorganic Chemistry (MTIC)‐XII, Dec’07, 
Indian Institute of Technology Madras, India 
“Biphenyl­Bridged Dicobaloximes: Synthesis, NMR, CV, and XRay Study” 
(poster presentation) 
All the details provided here are correct to the best of my knowledge 
National Symposia on Organic and Inorganic Interface, Dec’04 Indian 
Institute of Technology Guwahati, Assam, India 
   
LANGUAGES 
 
 
ANALYTICAL 
TECHNIQUES  
KNOWN & 
SOFTWARES 
FAMILIER  
 
 
English (fluent, ‐TOEFL score 94/120 in Feb’08), German (basic), 
Assamese (native), Hindi, Bengali 
 
NMR,  UV‐Visible  spectrophotometer,  FT‐IR,  Cyclic  Voltametry, 
Fluorescence Spectrophotometer 
 Chem  Draw,  ISIS  Draw,  ChemCraft,  Origin,  ShelXl,  WinGx,  Mercury 
1.2.1, enCIFer 
 
 
 
 
 
 
 
 
 
 
 
